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Aims of the study 
 
 
 
The main aim of this Master’s thesis is to contribute to the development of novel lead therapeutic 
compounds against prostate cancer. This is closely related to the aims of the TCMCANCER project. 
European exchange students at the MRCTCM are obliged to follow the “Description of Work” annex 
stated in the TCMCANCER project. The main aim of this study is divided into two intermediate aims 
(A. and B.). Intermediate aim A. entails the theoretical part while intermediate aim B. entails the 
practical part. 
 
 
 
A. Theoretical part: 
 
The first intermediate aim of this study is to present a literature review of general aspects involved in 
preclinical trials for the evaluation of efficacy and toxicity of novel lead therapeutic compounds 
against prostate cancer. Thus, this part encompasses sections about natural sources of medicinal drugs, 
available animal models, human and animal pharmacology, project design, monitoring methods and 
ethical aspects.  
 
 
 
B. Practical part: 
 
The second intermediate aim of this study is to present the isolation and characterization of secondary 
metabolites from the leaves and branches of Abies pindrow. Thus, this part encompasses sections 
about isolation and identification theory, materials, methods, results and discussion and conclusion. 
The TCMCANCER project states that European exchange students at the MRCTCM will isolate 
compounds from plants used in TCM to learn about the purification of natural products. The 
TCMCANCER project states further that knowledge about structure elucidation will also be acquired. 
Hopefully, further work with these isolated compounds will generate novel lead therapeutic 
compounds against prostate cancer.
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Summary 
 
 
 
Introduction: 
 
Plants and herbs have been utilized for centuries by traditional medicinal systems (e.g. TCM, 
Ayurveda) to alleviate minor illnesses and major diseases. In recent decades, interest in traditional 
medicine has increased significantly among drug development institutions. Currently, several research 
groups worldwide are conducting isolation, characterization and bioassay evaluation of secondary 
metabolites from plants and herbs utilized in traditional medicine. Such research aims to produce 
potential lead therapeutic compounds for future evaluation in preclinical animal models. Also 
terrestrial and marine organisms have been shown to produce biologically active secondary 
metabolites. In this Master’s thesis, key elements in the preparation of animal experiments for the 
evaluation of lead therapeutic compounds against adenocarcinoma of the prostate are presented. Thus, 
potential medicinal sources, prostate cancer animal models, pharmacology of humans and animals, 
study design, metastasis, monitoring techniques and ethical aspects are described. The practical part of 
this Master’s thesis is focused on the isolation and characterization of flavonoids from the branches 
and leaves of Abies pindrow. Previous purification of this plant species has been reported in the 
literature.  
 
 
 
Methodological considerations: 
 
Low-pressure column chromatography is dependent on four mechanisms of separation: adsorption, 
size-exclusion, partition and ion-exchange. Silica gel column chromatography is a form of adsorption 
chromatography. Sephadex LH-20 separates compounds mainly through size-exclusion, but 
adsorption can also be involved. Planar liquid chromatography comprises popular techniques such as 
TLC and PTLC, which are based on adsorption chromatography. MS and NMR are commonly 
employed in structure elucidation. MS is used to investigate molecular masses, while NMR describes 
the chemical environment of NMR active nuclei. 
 
 
 
Materials: 
 
A range of organic solvents were utilized in the isolation process. MeOH and CHCl3 were most often 
employed. Much of the work involved both TLC and PTLC plates. Sephadex LH-20 particles were 
employed more frequent than silica gel particles. The isolation process required equipment such as 
TLC and UV lamps, rotary evaporator and automatic fraction collector. MS and NMR analysis was 
performed to enable structure elucidation. 
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Methods: 
 
Only simple chromatographic techniques were used. Analytical silica adsorbent TLC was employed 
throughout the isolation process. Silica adsorbent PTLC and polysaccharide size-exclusion 
chromatography were frequently employed. Silica gel column chromatography was only performed 
twice. 
 
 
 
Results and discussion: 
 
Nine compounds were initially isolated and purified. Two purified compounds were found to be the 
same prior to MS and NMR analysis, thus, only eight compounds were analyzed by MS and NMR. 
Out of these eight compounds, three were not pure enough to enable structure characterization and two 
were identified as the same compound on the basis of resulting spectra. Therefore, the isolation and 
identification of flavonoids from Abies pindrow yielded a total of four structurally dissimilar 
compounds. 
 
 
 
Conclusion: 
 
Four structurally dissimilar compounds were isolated through the use of simple chromatographic 
techniques and identified by MS and NMR analysis. All of the identified compounds belong to a class 
of plant secondary metabolites called flavonoids, or more specifically; flavonoid glycosides. They are 
known as: (1) kaempferol-3-O-(2ʹʹ, 4ʹʹ-di-E-p-coumaroyl)--L-rhamnopyranoside, (2) kaempferol-3-
O--L-(4ʹʹ-E-p-coumaroyl)-rhamnoside, (3) quercitrin and (4) afzelin. Hopefully, investigation of 
these compounds on a molecular and cellular level will result in novel lead therapeutic compounds 
against cancer for future evaluation in animal models.
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Introduction 
 
 
 
1. Plants, herbs, fungi, bacteria and marine organisms 
 as a potential source of medicinal drugs 
 
 
1.1 Nature as a source of bioactive compounds 
 
Nature has long been exploited by humans as a source of biologically active chemicals utilized to 
maintain good health and restore imbalances among the ill. A generic term for such medicinal systems 
is Traditional Herbal Medicine (THM). Long before Western medicine was established, nature was 
considered holy, and thus, it was believed to possess divine healing and re-vitalizing powers. People 
used plants, animals and minerals to treat imbalances and restore inner energy. Approximately 80 % of 
people living in developing countries still hold on to these medicinal systems. Use of remedies from 
THM in industrialized countries has increased significantly in the last decade. Currently, many 
healthcare systems around the world have incorporated THM as part of their healthcare services. 
Researchers worldwide are devoting their work to the isolation and identification of chemical 
constituents and potential biological effects of compounds isolated from sources utilized in THM. 
Plants utilized in traditional medicinal systems, such as Ayurveda, Traditional Chinese Medicine 
(TCM), Traditional Unani Medicine, Traditional Western Herbal Medicine and Traditional Japanese 
Kampo Medicine, are all regarded as potential sources of bioactive compounds. [1] 
 
 
1.2 Panels of natural compounds 
 
International collaboration between research institutions have enabled construction of large panels 
consisting of isolated phytochemicals (i.e. chemical derived from plants). A project called “Natural 
Inhibitor of Carcinogenesis”, funded by the National Cancer Institute, has led to the collection of over 
5000 plant extracts, wherefrom more than 250 compounds have displayed anti-tumour activity. 
Research groups in India, Pakistan and Brazil are conducting similar research. The project developed 
by the TCMCANCER network called ”Traditional Chinese Medicine in the Post-Genomic Era: 
Identifying Lead Therapeutic Compounds Against Cancer” has led to the construction of the largest 
panel of natural compounds that currently exists in the People’s Republic of China. [1] 
 
Numerous preclinical and clinical trials in the literature seek to describe the molecular mechanisms 
underlying the anti-tumour activities of potential lead therapeutic compounds. Vast majority of 
evaluated compounds originate from natural sources in their initial structural forms, as derivatives or 
as semi-synthetic molecules. As a result, chemotherapeutics currently in use stem from different 
panels of natural compounds. Phytochemicals and natural compounds from both marine and terrestrial 
organisms have all been shown to display potential anti-tumour activities in various reports. Much 
work has been done in the last decade to increase our knowledge about TCM through evidence-based 
methodology in order to reveal biological activity of plant secondary metabolites from TCM in the 
search of lead therapeutic compounds against cancer. [2] 
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1.3 Aims of the TCMCANCER network 
 
The main goal of the TCMCANCER network is to identify lead therapeutic compounds against cancer 
and test them in preclinical animal models, which may subsequently lead to the development of new 
chemotherapeutics. This Master’s thesis serves as a supplement to the on-going scientific work 
performed by a research group at the Gade Institute in the field of oncology. This research group is 
particularly interested in adenocarcinoma of the prostate, which has resulted in the development of an 
in vitro cell model that enables screening of novel chemotherapeutic agents. The screening model 
developed at the Gade Institute is specifically utilized for the evaluation of activity against cancer stem 
cells. As a contribution to the aims of the TCMCANCER network and the work of the research group 
at the Gade Institute, this Master’s thesis is intended to provide an overview of how the panel of 
natural compounds at the MRCTCM is generated and expanded, and to describe key elements in 
preparation of animal experiments.   
 
The MRCTCM holds, at the present time, one of the largest collections in the People’s Republic of 
China of extracts and compounds isolated from plant material. To this date, as much as 65 % of 
traditional medicinal plants in TCM have been investigated in the laboratories of the MRCTCM. 
Plants have been collected from many different parts of the country. Over 6000 compounds have been 
isolated and characterized, wherefrom 454 had not been reported in the literature prior to their 
isolation at the MRCTCM. As many as 8000 extracts from 342 plant families traditionally utilized as 
Chinese herbal medicines have been investigated. This vast amount of work has been performed by 
students, scientists and professors at the MRCTCM under the leadership of Professor Zhang Wei-
Dong. In addition to building up their own Natural Product Library at the MRCTCM, information 
about each identified compound, such as CAS, name, category, structure, molecular formula, 
molecular weight, bioactivity and references, is all gathered in a database called Chinese Nature 
Products Database (CNPD). 
 
 
1.4 Plant secondary metabolites 
 
Although a lot of effort and money has been provided by governments all over the world to the field of 
cancer research, cancer still remains a leading cause of death worldwide. Much knowledge has been 
brought about in terms of cancer initiation and progression on a molecular level due to major advances 
in molecular and biological technology. Consequently, massive amount of research has been 
conducted to evaluate potential anti-tumour effects of plant secondary metabolites. Plants and herbs 
are traditionally utilized in TCM to prevent and alleviate minor ailments and major diseases. Research 
groups around the world are currently isolating, characterizing and evaluating potential therapeutic 
activities of plant secondary metabolites from TCM. Curcumin, berberine and genistein are just a few 
of the many plant secondary metabolites that have been shown to display chemotherapeutic properties. 
[3] 
 
1.4.1 Curcumin 
 
Curcumin is a conjugated, di-phenolic molecule that can be isolated from the plant species called 
Curcuma longa. Utilization of this plant as a medicinal source originates from Ayurveda (traditional 
medicine native to India) and TCM. Preclinical trials have demonstrated the ability of curcumin to 
both prevent cancer initiation and stimulate tumour regression. Thus, curcumin is regarded as a strong 
candidate for further research. However, clinical trials are impeded by its low bioavailability. Different 
strategies are currently being undertaken to improve the pharmacokinetics of curcumin. [4] 
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1.4.2 Berberine  
 
Berberine is a quaternary ammonium salt that belongs to a group of plant secondary metabolites called 
alkaloids. It is commonly utilized as medicinal remedy in TCM. An increasing number of studies 
dedicated to the evaluation of berberine as a potential lead therapeutic compound have led to the 
discovery of its anti-tumour activity. Berberine has been shown, among other anti-tumour properties, 
to be effective against murine prostate cancer cells by promoting DNA damage in malignant cells. [5] 
 
1.4.3 Genistein    
 
Genistein is a polyphenolic molecule that belongs to a group of organic compounds called isoflavones, 
and can be found in soybeans. Genistein is currently being investigated in clinical trials for the 
evaluation of its therapeutic effect on prostatic neoplasm through the support of the National Cancer 
Institute. In vitro studies of cancer cells have been shown to undergo apoptosis after treatment with 
genistein. Further studies of genistein need to be conducted in order to map its underlying mechanisms 
of action in malignant diseases. [6] 
 
 
1.5 Fungal and bacterial compounds 
 
Several molecules of fungal origin have been reported in the literature to inhibit molecular pathways 
involved in tumour initiation and progression. Actinomycete strains have been shown to produce a 
number of molecules with potential effects on carcinogenesis. Examples of potential lead therapeutic 
compounds against cancer of fungal origin are CGP049090, PKF118-744 and ZTM000990. Also 
bacterial species have been shown to produce molecules with anti-tumour activities. An example of a 
bacterium that has been evaluated with regards to potential effects against different neoplasms is 
Streptomyces conglobatus, which in fact has yielded positive findings. [2] 
 
 
1.6 Marine compounds 
 
Continuous search for improved methods of cancer prevention and treatment by authorities 
worldwide, has led scientists to the discovery of new strategies. Research in the field of oncology has 
long been centred on the utilization of plants, herbs and terrestrial organisms as sources of potential 
chemotherapeutics. Lately, however, this focus has slightly shifted, or at least expanded, towards 
utilization of marine organisms as well. Several interesting molecules have been isolated from marine 
organisms, thus, it appears that our seas harbour enormous medicinal sources that remain unexploited.  
 
Marine organisms have the ability to produce biologically active secondary metabolites due to the lack 
of innate immune systems. Secondary metabolites are utilized as protection against various diseases 
and harsh living conditions. Studies have demonstrated anti-tumour activity among several marine 
compounds. As a result, three marine compounds have in recent years been approved as 
chemotherapeutic agents by the FDA. These are trabectedin, cytarabine and eribulin mesylate. 
Biodiversity is much greater in the sea than on land, thus, marine organisms as a source of potential 
medicinal drugs will contribute immensely to the field of oncology for many years or even decades to 
come. [7] 
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2. Preclinical animal models of prostatic neoplasm 
 
 
2.1 General considerations 
 
The search for and development of novel therapeutic compounds, including anticancer drugs, can be a 
resource-intensive, time-consuming and costly process. In the field of oncology, such research usually 
starts with screening procedures of isolated and purified compounds in cell culture-based assays to 
detect and monitor anti-tumour activity. Properties characteristic of cancer cells (e.g. cell proliferation, 
migration, invasion) are utilized as targets in order to evaluate anti-tumour efficacy. Tumour 
specificity of novel chemotherapeutic agents can be assessed by monitoring apoptosis inducing effects 
in malignant cells compared to benign cells. Lately, cancer stem cell research has been dedicated 
increasing interest among scientists in the field of oncology. These cells are thought to be resistant 
towards conventional therapeutics and display high tumourigenic tendencies. Thus, future 
development of novel compounds against malignant diseases should also be focused on targeting 
cancer stem cells.  
 
 The goal of initial screening is to detect bioactive compounds. Initial screening and preclinical testing, 
together, serve to detect compounds with potential therapeutic applications, termed lead therapeutic 
compounds. Lead therapeutic compounds are utilized in modern drug development to develop novel 
therapeutic agents for use in patients. Thus, lead therapeutic compounds are necessary for the 
development of novel chemotherapeutics. 
 
Different panels of chemical compounds are utilized in initial screening. Further description of 
screening goals and strategies will not be provided in this Master’s thesis. For more information on 
this matter, a review article by Suggitt, M. and M.C. Bibby [8] is of more relevance. The goal of this 
Master’s thesis is to provide an overview of available animal models for future investigation of 
selected compounds from initial screening tests. In accordance with the focus of the research group at 
the Gade Institute in collaboration with the MRCTCM, the emphasis of this Master’s thesis is on 
animal models of prostatic neoplasm.  
 
Professor Kalland’s research group at the Gade Institute has developed a screening model for stepwise 
tumourigenesis of prostate cells based on physiological selection and adaptation by the use of benign, 
epithelial prostate cells. Such an approach is thought to yield a better representation of the clinical 
situation. Interestingly, cancer stem cells have been identified in this screening model. Thus, this 
model can be utilized to evaluate the efficacy of phytochemicals against the smaller sub-population of 
malignant cells represented by cancer stem cells. 
 
 
2.2 Animal models 
 
Rats are able to develop adenocarcinoma of the prostate spontaneously. The Dunning and the Lobund-
Wistar rat model are examples. However, the use of rat models in prostatic neoplasm research is 
limited due to the low incidence of adenocarcinoma, prolonged latency and poor ability of tumours to 
metastasize. Dogs are similar to humans with respect to high incidence of prostatic neoplasms, late 
onset of clinical symptoms and high susceptibility for bone metastasis. Limiting their use in research is 
the fact that dogs display wide variability in tumour growth, the pathophysiological mechanisms 
behind canine prostatic neoplasms are poorly understood and the cost of sustaining dog experiments is 
high. Mice have a life expectancy of about 3 years, which enables scientists to study the development 
and progression of cancer over a relatively short period of time. Also most of the genes participating in 
cancer lend themselves to genetic manipulation. On the other hand, mice are both anatomically and 
structurally different from humans. While cancer in mice often develops in mesenchymal cells, cancer 
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in humans usually originates from epithelial cells. Differences in carcinogenesis have also been 
observed. Regardless of the disadvantages, mice models have provided invaluable information on both 
pathogenesis and mechanisms in adenocarcinoma of the prostate. Awareness of both advantages and 
limitations of mice models can provide more accurate extrapolation to pathogenesis in humans. [9] 
 
 
2.3 Xenograft models 
 
Transplantation of human neoplasms into immunodeficient mice has been of great importance in 
research on prostate adenocarcinoma. Xenograft models can be used to continuously assess disease 
progression and has long been considered to be the animal model that is most similar to the complex in 
vivo situation of human prostatic neoplasms. Some implants even metastasize, providing animal 
models that can be used in preclinical drug evaluations. Although xenograft models have proven to be 
immensely useful in prostatic neoplasm research, they are not without flaws, which include 
diminished immunologic response in host, low incidence of tumour establishment and 
physioanatomical differences between host and donor. Also the fact that xenografted neoplasms are 
advanced tumours has excluded the possibility to monitor cancer initiation and progression in healthy 
exocrine glands. Xenograft models do not focus on the interactions between host and xenografted 
neoplasm. In addition, other more clinically relevant models have been developed since their 
emergence. Thus lately, researchers have suggested that they should only be used as an intermediate 
step in preclinical evaluations, placed between cell cultures and immunocompetent mouse models. [9, 
10] 
 
 
2.4 Mouse prostate reconstitution (MPR) models 
 
Foetal epithelial and/or stromal cells from the urogenital sinuses of mice are transplanted under the 
renal capsule of males with similar genetics, which produces an artificial organ. Oncogenes (e.g. ras 
and myc) are transferred to the transplanted cells through retroviral transduction. These cells have a 
high incidence of developing carcinomas. Metastasis can be increased by utilizing p53 knockout mice 
as donors of foetal urogenital sinus cells. The mouse prostate reconstitution model has been widely 
used for the evaluation of gene- and immunotherapy. On the negative side, these models require 
expertise in the field of molecular virology, the tumours are highly aggressive and bone metastasis is 
rarely achieved. Thus, evaluation of novel chemotherapeutics is highly restricted. [9, 10] 
 
 
2.5 Transgenic models 
 
Mutations in the mouse genome can provide excellent models for the study of adenocarcinoma of the 
prostate. As previously stated, no animal model is able to give a complete picture of the intricate 
tumour biology of prostatic neoplasms. Interpretation of data should for this reason rely on results 
from different animal models, thus, yielding a more detailed and accurate overview of cancer 
development and progression. Transgenic mice models are genetically engineered through the 
insertion of an exogenous gene into their genome by recombinant DNA technology. Molecular 
mechanisms of human carcinogenesis are conserved to some extent in mice, despite differences in 
species specific proteins. In models based on SV40 oncogenes, genes that code for tissue-specific viral 
oncoproteins are used to promote adenocarcinoma of the prostate. Two important mouse models are 
based on SV40 oncogenes, the TRAMP (transgenic adenocarcinoma of the mouse prostate) model and 
the LADY (LPB-Tag transgenic mice) model. The PSP-KIMAP model also displays promising 
features. [9, 10] 
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2.5.1 TRAMP models 
 
These models exhibit a high degree of metastasis to lymph nodes and lungs (approx. 100 %). The 
inserted genes are called SV40 large and small t antigen.  Large t antigen affects the functions of p53 
and retinoblastoma tumour suppressor genes, thereby leading prostatic cells into uncontrolled cell 
proliferation. Small t antigen stimulates both growth and survival of tumour cells by inhibiting the 
function of protein phosphatase 2A. TRAMP models display several important characteristics: latency 
period is relatively short, metastasis progression resembles human cancer and castration does not 
inhibit growth. For these reasons the TRAMP model has been used to investigate the molecular 
pathways leading to adenocarcinoma of the prostate and to evaluate new medicines. [9] 
 
2.5.2 LADY models 
 
In the LADY model, only the large t antigen is inserted. The absence of small t antigen results in a less 
aggressive adenocarcinoma of the prostate compared to the TRAMP model. LADY models have been 
used to assess the effects of fat and antioxidants on prostatic neoplasm development. This model can 
also yield more aggressive tumours with a high degree of vascularisation which are called 
neuroendocrine tumours. These tumours give worse prognosis and have shown to be resistant to 
chemotherapy. LADY models with neuroendocrine tumours can thus be used to reveal molecular 
pathways in neuroendocrine carcinoma, angiogenesis in tumours and the development of new 
medicines. The use of highly aggressive LADY models is however limited due to the low incidence of 
neuroendocrine carcinoma of the prostate in humans (1-2 % of prostatic neoplasms). [9] 
 
2.5.3 PSP-KIMAP models 
 
Both large and small t antigens are inserted. These models display prostate-specific expression with 
prostatic neoplasm developing after a 2 month latency period and metastasis to lungs, lymph nodes 
and liver in about 80 % of the models. [9] 
 
 
2.6 New transgenic models 
 
The SV40 oncogene-based models just presented, display a range of important features: high tumour 
incidence, androgen independence and high metastasis incidence. Thus, these models have been of 
significant importance in researchers’ quest to map the complexities of prostate carcinogenesis and to 
evaluate new drugs in preclinical studies. However, some drawbacks should be taken into 
consideration: neuroendocrine tumours might develop, carcinogenesis is induced by viral proteins and 
incidence of bone metastasis is low. Since the use of these models is focused on the investigation of 
late stage prostatic neoplasms, transgenic models of newer origin have been developed to study early 
stage prostatic neoplasms. This new generation of transgenic models, enabled due to advances in 
molecular technology, have alterations in a single or multiple genes. By gene deletion, mutation or 
insertion, a range of prostatic neoplasm models can be achieved. The most commonly employed 
targets for gene alterations are transcription factors, hormone receptors, growth factors and their 
receptors, and genes involved in cell cycle and apoptosis. For example, deletion of the PTEN gene in 
mice leads to development of prostatic intraepithelial neoplasm within a month or two. [9, 10] 
 
 
2.7 Allograft models 
 
Allograft models, also known as immunocompetent models, are developed by transplantation of 
tumour cells from one mouse into a genetically similar mouse. Thus, there is no need for athymic 
mice. Such a model allows the insertion of neoplasms at different stages in different locations. 
  Introduction 
7 
 
Initiation of metastasis and further progression can be observed within a relatively short period of 
time, contributing to their great importance in the area of preclinical drug evaluation. Through the 
intracardiac injection of cell line derivatives from TRAMP mice, a new bone metastatic model of 
immunocompetent mice has been developed. Such a model provides an important platform for 
preclinical drug evaluations in the presence of an intact immune system. [9] 
 
 
2.8 Mouse models in preclinical evaluations 
 
The many molecular and cellular stages of adenocarcinoma of the prostate, from healthy exocrine 
gland to adenocarcinoma, are all features of an ideal, non-existing mouse model. Nevertheless, current 
transgenic models have provided reasonable indications as what to expect from new therapies with 
regards to anti-tumour effectiveness and toxicity. As the new generation of transgenic mouse models 
represent only early stage prostatic neoplasms, they are of no use in the evaluation of drug 
effectiveness in late stage prostatic neoplasms. Regardless of this fact, transgenic mouse models have 
been extensively used in preclinical drug evaluations. Due to their close resemblance to the clinical 
situation in humans, TRAMP models have most frequently been used for the evaluation of new 
treatment regimens. A wide range of compounds have been preclinically tested by the use of TRAMP 
models (e.g. polyphenolics, retinoic acid and anti-androgens). [9] 
 
 
2.9 Stem cell research and cancer stem cells (CSCs) 
 
CSCs share several properties, especially the dual capability for unlimited self-renewal and for giving 
rise to progeny cells through asymmetric division. Accumulating data suggest that CSCs are the 
indispensable and essential cells for tumour growth and are relatively resistant to existing 
chemotherapeutic drugs due to a variety of escape mechanisms. The conventional approach for 
anticancer drug discovery is to target cell proliferation rather than self-renewal and/or differentiation, 
and so, is often biased to select targets with homogeneous expression patterns and potent compounds 
that kill the bulk tumour cells. According to the CSC concept, conventional therapy does not treat the 
root of the problem, which is the main reason for re-growth of the tumour following seemingly 
successful remission. The CSC concept provides a rationale for several therapeutic strategies beyond 
traditional anti-proliferative agents by focusing on the putative tumourigenic cells, known as cancer 
stem cells (CSCs) in cell-based assays. Potential approaches to kill CSCs include blocking essential 
self-renewal signalling, inhibiting the survival mechanisms or inducing tumour cell differentiation, 
which can potentially be achieved by inhibiting developmental pathways. [11, 12] 
 
 
2.10 Prostate cancer stem cell model developed at the Gade Institute  
 
The EPT model of experimental stepwise prostate tumourigenesis developed in Bergen during the last 
5 years, has led Professor Kalland’s research group at the Gade Institute in Bergen to the 
establishment of a stepwise prostate cancer cell model based on physiological selection and 
adaptation. This model represents the first successful tumourigenic prostate model started from benign 
cells without the use of external oncogenes. The founding EP156T cells are human, benign epithelial 
cells with basal cell features. EP156T cells underwent EMT (epithelial-to-mesenchymal-transition) 
when they were grown at full confluence for 4 months to select for cells with loss of cell contact 
inhibition. The new mesenchymal type of progeny cells were called EPT1 cells and exhibited 
increased capabilities of migration and invasion. EPT1 cells were grown at full confluence for 3 to 4 
weeks and foci appeared in the monolayer culture. Different from EP156T and EPT1 cells, cells from 
the foci form robust colonies in soft agar in 5 days. New EPT2 cells were cloned from soft agar 
colonies. In contrast to EPT1 cells, the majority of EPT2 cells can continue to divide after serum 
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depletion, exhibiting growth factor self-sufficiency. The selected EPT2 cells that grew well in serum 
free medium formed large subcutaneous tumours in mice. Cells obtained from the animal tumours 
were called EPT3. Following lentiviral introduction of a GFP-luciferase reporter construct, EPT3 cells 
were re-injected into mice prostate orthotopically. Extensive metastasis was found by in vivo 
bioluminescence imaging over 3 months. Cells collected from metastases were named EPT3-M1. 
DNA microsatellite analysis, karyotyping and genome-wide copy number analyses verified the genetic 
authenticity of all the different cells derived from this model and ruled out contamination with other 
laboratory cells. The identification and isolation of CSCs in the mice tumour and metastasis of this 
model makes it particularly interesting for testing compounds with activity against cancer stem cells. 
[13-15] 
 
 
2.11 Predictive value of preclinical studies 
 
So far, results from preclinical models have not been very predictive of results from clinical trials. 
Scientists and researchers have proposed several reasons for this inherent problem in the existing 
preclinical models. As mentioned earlier, no animal model gives a complete representation of prostate 
carcinogenesis. Thus, available preclinical models can be said to be inappropriate for prostatic 
neoplasm research. Another reason is that preclinical models might be used inappropriately due to 
discrepancies between the genotypic and phenotypic characteristics of a model and the therapeutic 
focus of the agent in question. A final reason might be due to major differences in the design of 
preclinical studies and human trials. The pharmacodynamic and pharmacokinetic variations in mice 
and humans should be accounted for in preclinical studies. Also drug administration and treatment of 
preclinical models should be the same in human trials. [16] 
 
 
2.12 Metastasis 
 
Metastasis requires a set of successive steps. The steps are divided as follows: (1) Tumour initiation: 
regulation of growth in a localized area is impaired and carcinogenesis is initiated. (2) Progression: 
further changes in regulatory mechanisms on both a molecular and cellular level promote invasiveness 
of tumour cells. (3) Intravasation: Acquired properties of tumour cells permit invasion of nearby 
tissue. (4) Transport: Invasion into blood vessels followed by subsequent transportation in the blood 
stream is dependent on the ability of the tumour cells to evade the immune system and suppress 
apoptosis. (5) Adhesion: transported tumour cells attach to blood vessels of other organs either non-
specifically or through the use of receptors. (6) Extravasation: uptake of tumour cells from blood 
vessels and invasion of surrounding tissue due to further changes in tumour cell genome and 
physiology. (7) Metastasis: tumour cells survive and continue to grow into tumours in a different area 
from where carcinogenesis was initiated. Still, very little is known about what happens in metastasis 
on a molecular level. If only one step was to be targeted by a chemotherapeutic agent, it would 
undoubtedly have major implications on treatment and improve patient prognosis considerably. [17] 
 
 
2.13 Useful models of metastasis 
 
The search for an animal model with metastatic characteristics similar to those of humans, such as 
androgen independence and metastasis to specific organs, is of upmost concern in the study of 
metastasis. Obviously, no animal model can give an exact representation of cancer initiation and 
progression in humans. Before the development of genetically engineered mouse models, 
immunodeficient mouse models were the model of choice for the investigation of metastatic 
mechanisms in prostatic neoplasm. The most frequent site of metastasis in humans suffering from 
adenocarcinoma of the prostate is bone metastasis. Animal models that demonstrate bone metastasis 
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often have long latency periods and display somewhat different bone metastases from those observed 
in humans. [17] 
 
Many articles covering xenograft models have been published and it is evident that such models can 
give valuable insights into the many stages of prostatic neoplasm. However, xenograft models have 
few, if any, good systems for the study of metastasis. Mouse prostate reconstitution (MPR) models 
where foetal epithelial and/or stromal cells from the urogenital sinuses of mice are implanted under the 
renal capsule of males can be used to assess cancer progression and detect host-tumour interactions. 
Highly specialized personnel and advanced equipment, though, is needed to perform studies in this 
type of model. Also no genetically engineered mouse model in current use has been able to produce 
bone metastasis to a desirable extent. Better metastatic models of human prostate cancer are necessary. 
Future metastatic models should lend themselves to facilitated use, display a high degree of bone 
metastasis and avoid the need for specialized knowledge in invasive implantation techniques. [10, 17] 
 
 
 
3. Basic concepts in pharmacology 
 
 
3.1 Pharmacokinetics 
 
Pharmacokinetics is concerned with the effects the body has on the drug in question. Thus, 
immediately after a drug has entered the body, principles of pharmacokinetics are applicable. 
Pharmacokinetics is divided into four separate areas as the drug passes through the many functions 
and organs of the human body: absorption, distribution, metabolism and excretion. [18] 
 
3.1.1 Absorption 
 
The area of absorption is investigated to enable description of how much time it will take for the drug 
to exert its pharmacologic effect. Absorption is dependent on three general factors: route of 
administration, method of absorption and other factors influencing absorption. [18] 
 
Administration can be further divided into enteral, parenteral and other non-enteral administration. 
Enteral administration means that the drug passes through the gastrointestinal tract and examples are 
oral, sublingual, buccal and rectal administration. Parenteral administration comprises the intravenous, 
intramuscular and subcutaneous route of administration. Other non-enteral administration forms 
constitute inhalation, topical, transdermal, intranasal, intrathecal, intraventricular and ophthalmic 
administration. [18] 
 
Methods of absorption can be further divided into passive absorption, active absorption and 
pinocytosis. Passive absorption is the most prevalent method utilized by drugs in order to enter the 
systemic circulation. A concentration gradient across the luminal side of the enterocytes and their 
interior causes drugs to move (diffuse) from an area of high concentration (the lumen) to an area of 
low concentration (the cytoplasm of enterocytes). The drugs should be small and fat soluble in order to 
cross the plasma membrane solely by diffusion. Active absorption works oppositely from passive 
absorption. Input of energy is required and drugs are transported from an area of low concentration to 
an area of high concentration. In pinocytosis cells engulf drug particles to bring them across their 
plasma membranes. [18] 
 
Other factors that can influence absorption are rate of dissolution, blood flow and contact time. The 
rate of dissolution has a great impact on absorption. If drugs dissolve quickly, their absorption times 
will be short and their pharmacologic effects will be observed short after administration. Blood flow 
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also affects absorption to a large extent. The intestine has high blood flow, thus drugs are more easily 
absorbed from the intestine compared to the stomach. Low blood flow in a cutaneous area where a 
drug is administered transdermally will reduce drug absorption, and as a consequence, pharmacologic 
effect. Contact time has to do with drug molecules being in contact with sites of absorption. If drug 
molecules find themselves away from sites of absorption for long periods of time, absorption will be 
reduced. Other drugs, food and beverages may also alter absorption. [18] 
 
3.1.2 Bioavailability 
 
Bioavailability is a term used to express the percentage of the administered drug that reaches the 
bloodstream. Bioavailability is strongly bound to and therefore affected by absorption. Along with the 
previously mentioned factors, bioavailability is also influenced by formulation, metabolism and 
surface area. Only intravenously administered drugs have 100 % bioavailability. Orally administered 
drugs never reach 100 % bioavailability due to the reasons mentioned above and because once 
absorbed by the intestine, drugs are transported to the liver by the hepatic portal vein (Latin: vena 
portae hepatis), where they are metabolized before being transported to the bloodstream. Surface area 
has to do with the area capable of absorbing drug molecules. The intestine has a large surface area, 
thus absorption is greater in the intestine compared to the stomach. Once in the bloodstream, drugs can 
be distributed throughout the body depending on drug characteristics and pharmacokinetic properties. 
Drugs can also bind to specific plasma proteins in the systemic circulation. Albumin is such a plasma 
protein. Bound drug is pharmacologically inactive (i.e. unable to exert therapeutic effect) while an 
unbound drug is pharmacologically active. [18] 
 
3.1.3 Distribution 
 
Drugs are first distributed to organs with the highest blood flow, meaning heart, liver, kidney and 
brain. Areas with lower blood flow then follow, meaning muscles, skin and fat. It is difficult to 
achieve high enough drug concentrations in bones due to very low blood flow in these parts of the 
body. Infections in the CNS might also be difficult to treat due to selective permeability of the blood-
brain barrier. Volume of distribution is a commonly employed term used to describe to what extent the 
administered drug is distributed between the systemic circulation and the rest of the body. It is called 
volume of distribution because it is a calculation of the volume needed to reach the same concentration 
of the administered dose as the concentration found in a blood sample. In simpler terms, a large 
volume of distribution describes a drug that is highly distributed throughout the body while a small 
volume of distribution describes a drug that is poorly distributed throughout the body and stays largely 
within the systemic circulation. [18] 
 
3.1.4 Metabolism 
 
Metabolized drugs are often no longer pharmacologically active (at least less active) and more 
hydrophilic. Of course exceptions from this general rule exist. As an example, pro-drugs have to be 
metabolized to gain pharmacologic activity. Metabolism is primarily conducted by the liver, but can 
also be performed by the skin, lung, kidneys and gastrointestinal tract. The major group responsible 
for drug metabolism is a diverse group of proteins known as cytochrome P-450 enzymes. 
Interindividual differences in drug metabolism can be due to many factors, among them genetics, 
comorbidity and polypharmacy. [18] 
 
3.1.5 Excretion 
 
The body excretes drugs in many ways, some more important than others. Drugs can be excreted 
through urine, faeces, bile, exhaled air, sweat, tears, saliva and breast milk. Renal excretion comprises 
glomerular filtration, proximal tubular secretion and distal tubular reabsorption. Drugs are primarily 
excreted through urine. Half-life (t1/2) is used to describe how long a drug will remain active before 
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being excreted. Half-lives vary greatly between drugs, ranging from only minutes to several days. A 
drug reaches steady state after about 5 half-lives. Thus, for a drug with a half-life of 1 hour, it will take 
5 hours for the drug to be completely excreted from the body. Clearance is used to describe how much 
of the drug is removed from the systemic circulation per unit time. Total body clearance comprises 
hepatic clearance, renal clearance and pulmonary clearance among others. Glomerular filtration rate 
(GFR) is used to describe the amount of drug removed from the systemic circulation by the kidneys. 
Renal diseases can therefore cause severe toxicity in patients taking medications that are primarily 
excreted through urine. Creatinine clearance can be calculated by the use of the Cockcroft-Gault 
equation, which in turn gives an estimation of GFR. [18] 
 
Tumours can have a profound effect on different organ systems and thereby alter their functions. This 
is particularly true for metastatic neoplasms. As a consequence, pharmacokinetics may also be affected 
to different extents. 
 
 
3.2 Pharmacodynamics 
 
Pharmacodynamics is concerned with the effects the drug in question has on the body. A graphic 
representation of drug response at different doses yields a graph similar to that of a normal 
distribution, called frequency distribution curve. Such a graph can be used to determine the median 
effective dose (ED50), the dose that produces a therapeutic response in 50% of patients. The median 
lethal dose (LD50), the dose that kills 50% of patients, is determined from preclinical studies alone. 
Median toxicity dose (TD50), the dose that produces a toxic effect in 50% of patients, is determined 
from toxic effects recorded in animal studies and in clinical trials. Therapeutic index is determined by 
comparing ED50 to LD50. A drug with a high therapeutic index is regarded much safer than a drug with 
a low therapeutic index. Blood samples are necessary to monitor drugs with low therapeutic indexes. 
Both the highest plasma concentration (peak level) and the lowest plasma concentration (trough level) 
are measured to prevent toxicity. [18] 
 
Drugs used to treat the same diseases are compared on the basis of four different features: potency, 
efficacy, safety and cost. A potent drug displays a therapeutic effect at low doses. An efficacious drug 
yields a high maximal therapeutic response. A safe drug has a high therapeutic index and thus displays 
a low incidence of adverse and toxic effects. A costly drug can produce great income for the 
manufacturer, but can also be too expensive to take part in government funded health services. [18] 
 
The mechanism of action for the majority of drugs is either to activate or inhibit a receptor, in a wide 
sense of the word. Drugs can be agonists, partial agonists or antagonists. An agonist produces the 
same response as the naturally occurring ligand. A partial agonist produces the same effect as the 
naturally occurring ligand, but is less efficacious. An antagonist competes with the naturally occurring 
ligand for binding site(s) and produces an opposite effect. [18] 
 
Drug interactions can have major implications on chemotherapy. Drugs can interact with food, 
beverages and of course other drugs. Studies have shown a 50% risk of experiencing an adverse drug 
effect when taking 5 medications simultaneously. The risk for patients taking 8 or more medications is 
almost 100%. Drugs can either increase or decrease the efficacy of one or both of the drugs involved. 
Drug interactions are classified as additive, synergistic, antagonistic or incompatible. Additive means 
that drugs with similar mechanisms of action yield a therapeutic response that is the summation of 
individual therapeutic responses. Synergistic effects are therapeutic responses that exceed the 
summation of individual therapeutic responses. Antagonistic means that one drug reduces or 
completely erases the therapeutic effect of another drug. Incompatible drugs go through a chemical or 
physical reaction when mixed together. Incompatibility is most common for parenterally administered 
drugs. [18] 
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4. Preclinical pharmacology 
 
 
4.1 Animal pharmacology 
 
Although animal pharmacology is ranked second compared to animal toxicology, it can generate very 
useful information. As an example, previous work in the field of animal pharmacology has 
demonstrated the lethal dose in 10 % of mice (LD10 = C (concentration) × T (time)) to be the same as 
maximum tolerated dose in humans (MTD = C (concentration) × T (time)). This relationship has later 
been confirmed by several scientists. LD10 in mice thus provides an excellent dose escalation target in 
phase I clinical trials. [19] 
 
 
4.2 Animal toxicology 
 
In the United States of America, animal species normally employed in animal toxicology are mice or 
rats and beagle dogs. Primates are usually required for biological therapeutics (e.g. monoclonal 
antibodies). In Europe, toxicology studies in mice and rats are enough to advance to phase I clinical 
studies, given the fact that both species display similar dose-toxicity profiles. Animal models have 
been shown to yield reliable predictions of human toxicity. However, certain limitations are apparent. 
Toxicities in one species can be completely absent in another. Thus, although murine models display 
serious toxicities, it might be that dogs or primates do not do so due to differences in metabolism. 
Animal toxicology is crucial to the determination of dose for first human exposure. [19] 
 
 
4.3 Modern drug development 
 
Pharmacological objectives in modern drug development can be divided as follows: 
 
 
1. Pharmacological profiling: any preclinical trial designed to assess drug affinity for a molecular 
target, its ability to stimulate, inhibit or otherwise affect a biochemical pathway, organs or 
another drug. [20] 
2. Safety profiling: any preclinical trial designed to assess adverse effects and other unwanted 
effects of experimental drugs on biochemical pathways, organs or another drug. [20] 
 
 
Specific recommendations are made for preclinical study design in order to enable applicability of data 
from animals to the pharmacology of humans. These recommendations are listed below (Table 4.1). 
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Table 4.1 Recommendations for preclinical study design 
 
Design feature Recommendation 
Animal model Conscious, no analgesics if possible, same as or close to phase I clinical 
trial conditions 
Test subject Rodent or other species normally used in toxicology, most appropriate 
species from a scientific point of view  
Statistical consideration Each animal should serve as its own control to reduce the amount of 
animals used  
Number of test subjects Enough to achieve statistically satisfying results 
Control group Perform placebo testing 
Route of administration Should be equal or close to phase I clinical trial route 
Drug formulation Should be equal or close to phase I clinical trial formulation 
Dose range Minimum three doses, including a maximum tolerated dose (MTD)  
High dose Investigate maximum tolerated dose, maximum dose limited by 
formulation, dose limit (1-2 g/kg) 
Pharmacokinetics Document systemic changes 
Endpoints Document blood pressure, heart rate, ECG, survival, death, etc. 
Duration Enough to document drug distribution, Cmax, AUC 
Study execution Should be performed in accordance with Good Laboratory Practice 
Standards (GLPS) 
Source: Kinter, L.B. and J.P. Valentin [20] 
 
 
 
4.4 Biomarkers 
 
Drugs can bind to and alter the functions of molecular targets such as proteins (e.g. receptors, 
enzymes, transporters), carbohydrates, lipids or nucleic acids and thus re-establish homeostasis in 
certain cells, tissues or organs. If the physiological response to the drug is over a distinct tolerable 
level, opposing physiological mechanisms are activated and the outcome may be an increase/decrease 
in cell size or number, apoptosis or carcinogenesis. [20] 
 
Unwanted and toxic effects might be a direct consequence of the drug’s mechanism of action or high 
concentrations of the drug in body fluids and tissue. However, signals involved in the progression 
from initial drug-target interaction to irreversible physiological mechanism can be detected and used to 
monitor unwanted effects, thus facilitating risk assessments. These signals are called biomarkers and 
are utilized in modern drug development to predict efficacy and safety of experimental drugs in 
humans before conducting phase I clinical trials. Biomarkers are associated with molecular 
mechanisms that can be physically measured when performing in vitro screening and in vivo studies. 
In other words, biomarkers are used to enable extrapolation of findings in preclinical trials to findings 
in clinical trials with greater certainty. Molecular markers in animals must be associated with 
endpoints measurable in humans in order to be termed biomarkers. [20, 21] 
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5. Magnetic resonance imaging 
 
 
5.1 Doxorubicin in TRAMP models 
 
In order to validate the use of MRI in efficacy studies, Degrassi et al. [22] employed the use of this 
non-invasive technique to assess tumour regression in TRAMP models treated with doxorubicin. 
Poorly differentiated and well differentiated adenocarcinomas were successfully separated through the 
use of MRI. 3 out of 6 mice with poorly differentiated adenocarcinomas relapsed within 40 days after 
completed treatment. The MR images of these mice showed heterogeneities due to necrotic and 
haemorrhagic tissue. The mice with well differentiated adenocarcinomas were followed for 4 weeks 
after completed treatment, by which time all of the mice had relapsed and tumour sizes were larger 
than pre-treatment sizes. The usefulness of MRI in preclinical trials is evident. Not only does it allow 
us to follow both tumour regression and relapse, but it can also be used to distinguish between poorly 
differentiated and well differentiated adenocarcinomas. [22] 
 
 
 
6. In vivo bioluminescence imaging (BLI) 
 
 
6.1 Luciferase imaging 
 
Major breakthroughs in the fields of molecular and cellular biology have enabled the development of 
several imaging techniques for use in real-time analysis. In vivo luciferase imaging is one well-known 
example. Natural light production is oftentimes brought about by a class of enzymes called luciferases. 
The best studied luciferase is the one derived from the North American firefly (Photinus pyralis). 
Luciferases generate light by catalyzing oxidation reactions. Luciferase from the North American 
firefly emits green light with a wavelength of 562 nm. Luciferase from the sea pansy (Renilla 
reniformis) generates blue light with a wavelength of 482 nm. [23] 
 
6.1.1 Requirements 
 
Before in vivo imaging can commence, cells under investigation need to be transfected with the 
bioluminescent reporter gene, thus, genetic engineering is required. Once engineered cells have been 
transferred to an animal model, their location can be detected through the provision of luciferase 
substrates. No cofactors are required for catalysis by Renilla luciferase. Catalysis by Photinus 
luciferase, on the other hand, requires oxygen, magnesium and energy input in the form of ATP. [23] 
 
 
 
7. Small animal PET-CT and tumour assays 
 
 
7.1 PET 
 
PET (positron emission tomography) is enabled by the use of a radioisotope. Either a compound that is 
natural to the biology of the test animal or a drug under investigation is labelled with the radioisotope. 
The radioisotope emits a positron that annihilates with an electron yielding two γ-rays that travel in 
opposing directions. Both quantity and localization of the positron emitting substance is revealed. PET 
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sensitivity is generally considered to be very high. If two radioisotopes were to be used at the same 
time, the detector would not be able to distinguish between them. [21] 
 
 
7.2 CT 
 
 In the case of CT (computed tomography), X-rays are projected towards an animal model by the use 
of an X-ray source. A detector on the opposite side of the X-ray source measures the extent of 
absorption. X-ray is projected from every angle to enable production of structural images. CT 
resolution is generally considered to be high. On the other hand, sensitivity is not very good and it is 
difficult to utilize contrast agents as labels. Thus, CT is used in combination with different molecular 
imaging techniques rather than by itself. In the clinic, PET-CT has become first-line of diagnosis 
among molecular imaging methods. [21] 
 
 
7.3 Tumour assays 
 
Many assays have been developed to evaluate drug efficacy. Tumour growth delay assay and survival 
time assay are commonly employed in modern drug development. Tumour delay is described as the 
time it takes for a treated tumour to reach a certain size minus the time it takes for an untreated tumour 
to reach the same size (Figure 7.1). Survival times can reach a maximum point, above which the 
adverse effects outweigh beneficial effects. Survival time is described as the time treated animal 
models survive minus the time untreated animal models survive (Figure 7.2). [24] 
 
 
 
Figure 7.1 Tumour growth delay assay 
 
 
 
  Source: http://www.springerimages.com/Images/MedicineAndPublicHealth/1- 
   10.1007_s00280-009- 1099-1-1 
 
  Introduction 
16 
 
Figure 7.2 Survival time assay 
 
 
 
 
  Source: Chen, K.Y., et al [25] 
 
 
 
8. Animals in research 
 
 
8.1 Animal welfare 
 
The well-being of laboratory animals has been greatly improved due to William Russell and Rex 
Burch. In 1959, they proposed the “3Rs”, which apply to the use of animals in biomedical research. 
Their proposal were the following three principles: [26] 
  
 
1. Studies should cause the minimum amount of pain and distress in animals, and should 
therefore be refined accordingly. [26] 
 
2. In studies expected to cause pain and distress, the number of animals should be reduced. [26] 
 
3. If studies permitted so, animals able of feeling pain and distress should be replaced by non-
animal models. [26] 
 
 
Russell and Burch’s contributions to animal welfare are still essential to the requirements made today 
by regulatory authorities prior to approval of animal studies. In America, the local Institutional Animal 
Care and Use Committee (IACUC) evaluate animal study applications with two norms in mind: (1) 
infliction of untreated pain and distress in laboratory animals must be justified, and (2) infliction of 
untreated pain and distress in laboratory animals can be justified. “The Principles”, published in 1985 
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by the United States Interagency Research Animal Committee, gives a set of guidelines in the use of 
animals in preclinical studies and other animal research. The major concepts presented in this 
publication, as well as in the two main laws in America currently regulating animal research, are the 
concepts that follow: [26] 
 
 
 That which is painful to humans, should be assumed painful to animals. [26] 
 
 Good scientific practice searches to minimize and even avoid pain and distress in animals. [26] 
 
 Tranquilizers, anaesthesia, analgesia and even euthanasia can be withheld only when 
scientifically justifiable. [26] 
 
 
 
8.2 Euthanasia in pain management 
 
Killing, or euthanasia which is a more appropriate term, is regarded as the ultimate analgesic and is 
therefore often the first-line treatment of pain in research animals. Euthanasia does not require 
justification, but it is rather the avoidance of killing animals in pain and distress that necessitates 
justification. Pain due to cancer is a typical example. Pain management in the different forms of this 
disease requires increasingly more potent analgesics (e.g. fentanyl, morphine). Effective pain relief 
calls for intravenous drug administration, which would be rather difficult to implement in current mice 
cancer models. Analgesics can in addition have an effect on cancer progression. Euthanasia is thus the 
strategy of choice in cancer studies when addressing pain. [26] 
 
 
8.3 Progresses and trends 
 
The ultimate goal of public policies is to neither inflict pain nor distress in laboratory animals, 
something that seems rather idealistic and somewhat impossible. However, major progresses have 
been made to develop alternatives to animals and to reduce pain and distress in animals used in 
biomedical research. Whether the goal of zero pain and distress is realistic or not, consensus among 
regulatory authorities is that scientist at all times should strive for humane treatment of laboratory 
animals to ensure unnecessary infliction of pain. [26] 
 
Based on annual reports for 2002-2009 from the IACUC to the U.S. Department of Agriculture, 
animals that are deliberately left untreated for pain represent just under 10% of all animals used in 
biomedical research and that the number of these animals declines for each year. However, the reports 
from the IACUC describe only Animal Welfare Act-covered species which are estimated to be only 
1% of all research animals. Prostatic neoplasm research is performed mainly in mice, thus, it is 
impossible to know whether or not the annual reports from the IACUC give a true representation of 
pain management in mice since mice are not covered in the Animal Welfare Act. Another major 
drawback in the annual reports received by the U.S Department of Agriculture, is the fact that if 
previously conducted animal studies were to be performed by today’s standards, many animals would 
be placed in the same pain management category, whereas previously they were kept in separate 
categories. Also the IACUC reports combine pain and distress, making it impossible to differentiate 
between animals with pain and those with distress but without pain. Regardless of the lack of data for 
mice and other rodents, the amount of pain in Animal Welfare Act-covered species must in reality be 
reducing due to the fact that the amount of animals left untreated for pain have diminished over the 
years and the threshold for placing animals in this category has been lowered. [26] 
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9. Modern Research Centre for Traditional Chinese 
 Medicine (MRCTCM) 
 
 
9.1 Objectives 
 
The Modern Research Centre for Traditional Chinese Medicine is a research department at the Second 
Military Medical University in Shanghai. The objectives of this research department are to promote 
globalization of and establish a new research platform of TCM. Professors, scientists and students at 
the MRCTCM employ approaches and methods in structural biology, chemical biology, medicinal 
chemistry, analytical chemistry, pharmacology and toxicology.  
 
 
9.2 Natural Products Library 
 
342 plant families traditionally utilized in TCM have been systematically investigated through 
purification and identification. More than 6000 compounds have been characterized, wherefrom 
approximately 454 had not been reported in the literature prior to their isolation at the MRCTCM. 
Professors, scientists and students continuously publish results from their own work at this research 
department, and thus, contribute immensely to the globalization of TCM. The vast amount of work 
performed at the MRCTCM has enabled the construction of a Natural Products Library. About 8000 
standard TCM extracts and over 6000 purified and characterized organic compounds constitute the 
Natural Products Library. This library is currently the largest library of natural products in the 
People’s Republic of China.  
 
 
9.3 Phytochemistry laboratory 
 
The practical part of my Master’s thesis was performed in the Phytochemistry laboratory at the 
MRCTCM by the help of Dr. Li Yong-Li. This man is a Ph.D. student at the Shanghai Jiao Tong 
University who performs his laboratory work at the MRCTCM. Upon my arrival to Shanghai, Dr. Li 
Yong-Li was gathering extracts from a plant called Abies pindrow. Therefore, the practical part 
consisted of isolation and characterization of compounds from this particular plant. 
 
 
 
10. Abies pindrow 
 
 
10.1 Background information 
 
Abies pindrow (Family: Pinaceae) has a conical shape, levelled branches and needle-like leaves 
(Illustration 10.1). It grows in the Himalayas between the altitudes of 1600-4500 m above sea level. 
The use of this species as a medicinal plant is evident due to its mentioning in Ayurveda. Abies 
pindrow leaves have been utilized as traditional medicine in India to treat fever, inflammatory 
diseases, bronchitis and other ailments. [27, 28] 
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Illustration 10.1 Abies pindrow 
 
 
 
          Source: http://en.wikipedia.org/wiki/File:Abies_pindrow.jpg 
 
 
 
10.2 Pharmacological actions 
 
Studies have reported that extracts of Abies pindrow display anti-inflammatory, analgesic, anti-
ulcerogenic, anti-stress and hypotensive activities in preclinical animal models. Previous isolation of 
compounds from Abies pindrow has led to the discovery that both the stem and the leaves contain 
flavonoids. [27, 28]
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11. Low-pressure column chromatography 
 
 
11.1 Different techniques 
 
The term column chromatography covers a wide range of chromatographic techniques, all central to 
the isolation of natural products. Although the methods within this group are numerous, they share a 
common feature; solvent (the mobile phase) of a certain composition is allowed to flow through the 
pores of densely packed sorbent (the stationary phase) with a given particle size. The separation of 
compounds is made possible through one or several types of interactions between the compounds and 
the phases. [29] 
 
Compounds are selectively distributed to different extents between stationary and mobile phase. 
Differences in distribution coefficients are due to both chemical and physical characteristics of the 
phases and the compounds. Four important mechanisms of separation exist in column 
chromatography: adsorption, size-exclusion, partition and ion-exchange. [29] 
 
Silica gel and alumina belong to the group of sorbents utilized in adsorption chromatography. If the 
interactions between a compound and the adsorbent are much greater than the interactions between the 
compound and the mobile phase, the rate of migration will be low. Evidently, if the affinity for the 
mobile phase is much greater, the rate of migration will be high. Some of the types of interactions in 
absorption chromatography are hydrogen bonding, van der Waals forces and dipole-dipole 
interactions. Separation is oftentimes due to a combination of these interactions. [29] 
 
Size-exclusion chromatography, also called gel permeation chromatography, is as the name says a 
technique to exclude molecules based on size. The stationary phase consists of porous beads, which 
are easily penetrated by smaller molecules. Larger molecules, in contrast, are not able to penetrate the 
stationary phase particles. As a result, larger molecules elute faster than smaller molecules. [29] 
 
A difference in distribution of compounds between two different liquids is the basis of partition 
chromatography. This type of chromatography employs both a liquid stationary phase, immobilized 
onto a solid support, and a liquid mobile phase. If a compound is largely distributed in the mobile 
phase compared to the stationary phase, obviously, that compound will elute first. [29] 
 
For compounds that can carry a charge at a given pH value, the technique of ion-exchange 
chromatography is applicable. The sorbent contains charged groups that can interact with ionized 
groups on the compounds. Thus, separation is attributable to differences in charged groups. [29] 
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11.2 Silica gel chromatography 
 
As mentioned above, silica gel is utilized in adsorption chromatography. Silica gel is in fact the most 
commonly employed adsorbent in low-pressure column chromatography. One of the greatest 
advantages of silica gel is that it is highly inert. The adsorbent in silica gel chromatography is polar, 
thus, the more polar compounds will be retained to a greater extent compared to the more non-polar 
compounds. [30]  
 
11.2.1 Properties of silica gel 
 
Silica gel is a highly porous polymer composed of silicon oxide units (SiO2). In low-pressure column 
chromatography, silica gel particles in the size range of 40-200 µm are normally used. Silanol groups 
are exposed on the surface of silica gel particles (Figure 11.1). These silanol groups form the basis of 
adsorption to silica gel. Separated compounds can form many, few or no hydrogen bonds with the 
exposed silanol groups in the silica gel depending on characteristics of both the compounds and the 
mobile phase. [30] 
 
 
 
Figure 11.1 Exposed silanol groups on silica gel 
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11.2.2 Mobile phases 
 
Both non-polar solvents and polar solvents are employed in silica gel chromatography. If the mobile 
phase has many hydrogen bonding sites, the more capable it is of eluting polar compounds. Non-polar 
solvents such as hexane and dichloromethane are normally employed in silica gel chromatography. 
Conversely, regularly employed polar solvents are methanol, ethyl acetate and acetonitrile. Water and 
methanol can dissolve silica gel and consequently pollute the isolated products. [30] 
 
 
11.3 Size-exclusion chromatography 
 
A variety of polymers, such as polyacrylamide and different carbohydrates, can be utilized in size-
exclusion chromatography.  
 
11.3.1 Polyacrylamide 
 
Polyacrylamide (Bio-Gel P) is used to separate macromolecules like carbohydrates and peptides. 
Polyacrylamide particles range in size from 45 to 180 µm. Bio-Gel P gels are almost always operated 
with water as the mobile phase. Different gels provide separation of different molecular weights. [30] 
 
11.3.2 Carbohydrates 
 
Carbohydrates serve as a highly inert group of polymers. In size-exclusion chromatography, 
polysaccharides are crosslinked and formed into beads. A commonly utilized polysaccharide is 
dextran. The size of the beads can range from 20 to 300 µm, all with varying porosities.  
 
11.3.2.1 Sephadex 
 
Sephadex is probably the most commonly employed polymer resin in size-exclusion chromatography. 
Its preparation consists in crosslinking dextran with epichlorohydrin. These gels are named after how 
much solvent they pick up upon swelling. As an example, Sephadex G-50 picks up 5.0 mL of solvent 
per gram of polymer. Sephadex is able to separate molecular weights ranging from 10 to 100,000 Da. 
The most commonly employed Sephadex gels in natural products isolation is Sephadex G-10, G-15 
and LH-20. 
 
Sephadex LH-20 is regularly used for the separation of non-polar and semi-polar compounds. This gel 
is used to separate natural products with molecular weights of 100 to 4,000 Da. When utilized solely 
on the basis of size-exclusion, only a single solvent is used.  
 
 
 
12. Planar liquid chromatography 
 
 
12.1 TLC 
 
Among the techniques that belong to the group called planar liquid chromatography, thin liquid 
chromatography (TLC) is by far the most common one. This is greatly due to its inexpensiveness and 
its ease of use. TLC can be simply described as the separation of mixtures on thin layers of adsorbents 
coated on plastic, aluminium or glass. [29]
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The mixture to be investigated is applied as a spot onto the adsorbent and placed in a tank with a 
solvent of appropriate quantity and composition. The solvent should wet the bottom of the plate but 
not the part where the spots are applied. The plate is left to develop in the tank, i.e. the solvent 
migrates through the sorbent by capillary action and separates the mixture along the way. [29] 
 
 
12.2 Retardation factor (Rf) 
 
The Rf value of a given compound with a given sorbent and solvent system is an important measure 
that is characteristic of each compound, and thus, serves to both detect and distinguish between similar 
and dissimilar compounds, respectively. The Rf value of a compound is calculated as follows: [29] 
 
 
solventofcedisMigrated
compoundofcedisMigrated
R f
tan
tan
  [29] 
 
 
As can easily be predicted from the above quotient, Rf values are always between 0 and 1. As 
previously mentioned, the Rf value of a compound will vary in different sorbent and solvent systems. 
In the case of silica and alumina sorbents, polar compounds will migrate to a lesser extent due to a 
greater affinity for the sorbent (stationary phase). Non-polar compounds, in contrast, will interact more 
with the solvent system (mobile phase) compared to the sorbent. Compounds are thus separated with 
regards to polarity, which in turn is dependent on the type and number of functional groups present on 
the compounds in the mixture. As a result, polar compounds will have small Rf values, whilst non-
polar compounds will have large Rf values. [29] 
 
 
12.3 Partition and reverse phase TLC 
 
In most TLC experiments the mechanisms of separation are restricted to the mechanisms of adsorption 
and partition. The former has already been presented in the above section. Partition relies on 
differences in solubility of the compounds in the mixture with the stationary phase and the mobile 
phase. In other words, hydrophilic compounds will migrate less than hydrophobic compounds. In 
reverse phase TLC (i.e. non-polar stationary phase and polar mobile phase) the most commonly 
employed sorbent is octadecasilyl, which essentially is silica with attached C-18 aliphatic, unbranched 
units (Figure 12.1). In this mode, the extent of migration will be the other way around. Compounds 
that are hydrophilic will migrate to a greater extent compared to compounds that are hydrophobic. [29] 
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Figure 12.1 Octadecasilyl 
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12.4 Analytical TLC 
 
During an isolation process it is routine to perform analytical TLC in order to identify and monitor 
compounds. Compounds contained in fractions from different elution techniques (e.g. silica gel 
chromatography, dextran gel chromatography) and from other chromatographic techniques (e.g. 
PTLC) are normally monitored by the use of TLC. Because different compounds may have matching 
Rf values, it is advisable to develop the same sample in two different solvent systems. This way, 
seemingly “pure” spots may be confirmed as consisting of several compounds and spots from different 
fractions may be confirmed to be the same compound. [29] 
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12.5 Solvent system 
 
TLC is run either isocratically or by the use of a step-gradient. In the isocratic mode, the plate is 
developed in a solvent system of constant composition, whereas in the step-gradient mode, the plate is 
developed in a solvent system where the solvent polarity is gradually increased, thus, the power of 
elution is increased stepwise. [29] 
 
 
12.6 Detection 
 
Visualization of the isolated compounds is essential to the end result of the isolation process. Poor 
detection may lead to low yield of compounds and difficulties in obtaining compounds of required 
purity. Detection can be carried out in a destructive (e.g. spray reagent) or a non-destructive (e.g. UV-
light, I2) manner. A spray reagent consisting of 1 g vanillin powder, 90 mL of ethanol and 10 mL of 
concentrated sulphuric acid was routinely used during the isolation process. Destructive detection 
contaminates the compounds and renders recovery from the sorbent impossible. Non-destructive 
detection is therefore the method of choice if subsequent recovery is intended. [31] 
 
 
 
13. PTLC 
 
 
13.1 The role of PTLC 
 
Preparative thin layer chromatography (PTLC) is a popular separation method among natural 
chemistry laboratories, for the same reasons as for TLC. Lately, though, an increase in the use of more 
advanced techniques such as high-performance liquid chromatography (HPLC) and counter current 
chromatography have slightly shadowed the use of PTLC. Even so, for reasons to be presented in the 
following sections, PTLC still holds an important role in the isolation of natural products. [29] 
 
PTLC is oftentimes the last isolation step in an isolation process, and normally mixtures containing no 
more than 4 major components are developed. PTLC makes it is possible to isolate compounds in the 
1 mg to 1 g range in a relatively short period of time, which is one of the main reasons why PTLC 
remains such an attractive separation method. Commercial plates are available in the sorbents silica, 
alumina, C-18 and cellulose, but it is also possible to make your own plates if cost is a concern or if 
the mixture in question requires enhanced separation. [29]
 
 
 
13.2 Procedure 
 
The material to be separated on a PTLC plate should be dissolved in as little solvent as possible. The 
sample is applied approximately 1.5 cm from the bottom as a line about 5 mm in thickness by the use 
of a micro syringe or a capillary tube. Thinner capillary tubes give more concentrated lines, and thus, 
better separation. It is advisable to carefully draw a straight pencil line before applying the sample. 
The area about 1 cm from the plate edges should not be covered with sample because of “edge 
effects”, i.e. rapid movement of solvent along the edges resulting in irregular separation bands (Figure 
13.1). [29] 
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Figure 13.1 PTLC plate with “edge effects” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The tank used for developing plates is normally filled with 100 mL freshly made solvent. If the 
atmosphere in the tank is saturated with solvent, the separation process will be improved. Direct 
sunlight should be avoided during development due to the possibility of degradation. When the solvent 
front has either reached or is very close the top of the plate, the plate is taken out and left to air-dry in 
a fume cupboard. [29] 
 
In the case of silica plates with UV fluorescent indicator incorporated into the sorbent, the compound 
of interest is lightly marked with a pencil and scraped off the backing plate onto a piece of paper with 
a spatula. If the compound of interest does not absorb UV-light, a piece from the side of the plate 
(approximately 2 cm) is cut off followed by spray detection. The contaminated compound is obviously 
not combined with the scrapings from the unsprayed plate. [29] 
 
The sorbent particles are transferred to a conical flask, crushed to finer particles and added solvent. 30 
minutes should be enough time to allow desorption, after which time the suspension is filtered. 
Desorption should be repeated at least two times. Recovery of the product can also be obtained by 
placing the sorbent particles in a sintered glass funnel on top of a glass Buchner flask to which vacuum 
is applied (Illustration 13.1). Desorption takes place by washing the particles with solvent, which is 
repeated until recovery is deemed complete. [29] 
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Illustration 13.1 Desorption by applying vacuum 
 
 
 
Source: http://en.wikipedia.org/wiki/B%C3%BCchner_funnel 
 
 
 
14. Mass Spectrometry (MS) 
 
 
14.1 Function and instrumentation 
 
This spectrometric technique is, as the name indicates, used to investigate the mass of compounds, 
either known or unknown. The sequence in a mass spectrometer is simple; the compound is first 
ionised, the resulting ions are then separated with regards to their mass/charge ratios and finally a 
spectrum presents the number of ions as a function of mass/charge (m/z). It is normal to couple a mass 
spectrometer to an isolation method (e.g. gas or liquid chromatography). Other spectrometric 
techniques such as IR and NMR are normally used in conjunction with MS to aid the identification 
process, especially for unknown compounds. [32] 
 
The methods by which a compound is ionised and separated are in most cases independent of each 
other. Mass spectrometers can be divided into two major groups; low-resolution and high resolution 
instruments. The low-resolution instruments can separate ions with m/z of up to 3,000. The high-
resolution instruments, on the other hand, can distinguish between ions with m/z of up to 100,000. As 
described earlier, entry of the sample into the ionisation chamber is often achieved by coupling the 
mass spectrometer to a chromatograph, but the sample can also be introduced by direct insertion. The 
methods of ionisation and separation are plentiful. [32] 
 
 
14.2 Gas-phase ionisation methods 
 
These methods of ionisation are among the most commonly employed methods. The only requirement 
for the use of these techniques is that the vapour pressure of the compound be above a certain limit. 
Mainly non-ionic organic compounds with molecular weights under 1,000 are ionized by gas-phase 
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ionisation methods. Examples of gas-phase ionisation methods are electron impact ionisation (EI) and 
chemical ionisation. [32] 
 
 
14.3 Desorption ionisation methods 
 
Desorption ionisation can be described as sample molecules being emitted directly into the vapour 
phase as ions. Compounds normally subjected to this type of ionisation are large, non-volatile or ionic. 
The main drawbacks are that the molecular ion is not always obvious and the spectra are oftentimes 
complicated by ions in the matrix. [32]
 
 
 
14.4 Evaporative ionisation methods 
 
Evaporative ionisation methods have become very attractive since the direct coupling to a 
chromatograph was made possible. There exists two important methods; thermo spray ionisation and 
electro spray ionisation (ES). [32] Since the thermo spray method has been largely surpassed by the 
electro spray method, only the latter will be described.  
 
14.4.1 Electro spray ionisation 
 
Because the ionisation chamber in the electro spray mass spectrometer is operated at atmospheric 
pressure, this method is also called atmospheric pressure ionisation. The sample is introduced into the 
ionisation chamber through a capillary surrounded by a flow of nitrogen gas. The capillary tip is 
maintained at a high potential which in turn generates charged droplets. These droplets are directed 
towards the analyzer by the nitrogen gas. As the solvent evaporates, the electrostatic repulsion 
between the ions reaches a critical point which results in their release (“Coulombic explosion”) 
(Figure 14.1). Electro spray is mainly used on compounds able to carry multiple charges (e.g. 
proteins, peptides). [32] 
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Figure 14.1 Generation of droplets followed by columbic explosion in an 
electro spray ion source 
 
 
  
Source: http://www.chm.bris.ac.uk/ms/theory/esi-ionisation.html 
 
 
 
14.5 Mass analyzers 
 
After ionisation, the ions need to be separated. This can be achieved in a number of ways, with each 
mass analyzer comprising its own set of features. Some of the most important mass analyzers are 
magnetic sector analyzers, quadrupole mass analyzers, ion trap analyzers, time-of-flight-analyzers and 
Fourier transform analyzers. Only the ion trap analyzer will be presented in greater detail. 
 
14.5.1 Ion trap analyzer 
 
The ion trap analyzer has proven to be even more sensitive than the quadrupole mass analyzer. The 
name of this type of analyzer comes from the fact that ions can be “trapped” in the analyzer for a 
period of time before being ejected onto a detector. The ion trap analyzer is composed of three 
electrodes; one ring electrode and two end cap electrodes at both ends (Figure 14.2). The ring 
electrode is kept at a variable radio frequency, while the end caps can be maintained at ground 
potential, at a DC or at an AC voltage. There are three ways to separate ions with an ion trap analyzer: 
[32] 
 
 
1. A starting radio frequency voltage is gradually increased. 
- Ions above a given m/z value will be trapped and ejected in order as the radio frequency 
voltage increases. [32] 
  
2. A DC voltage is set across the end cap electrodes. 
- Ions both above and below a given m/z value will be trapped, which makes the ejection of ions 
highly selective. [32] 
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3. An auxiliary field is set between the end cap electrodes in addition to a DC voltage. 
- Selective ions gain kinetic energy which can be used to either further fragment ions or to reject 
unwanted ions. [32] 
 
 
 
Figure 14.2 An ion trap mass analyzer 
 
 
 
 
Source: http://people.stfx.ca/tsmithpa/Chem361/labs/ms.html 
 
 
 
14.6 Index of hydrogen deficiency 
 
Once the molecular formula of the compound has been obtained, it is possible to calculate what is 
called the “index of hydrogen deficiency”. This term can be explained as a comparison of the 
discovered formula with the formula of the corresponding saturated compound, in order to calculate 
how many pairs of hydrogen atoms need to be removed from the corresponding saturated compound 
for the two formulas to be in agreement. Hydrogen deficiency arises from cyclization and multiple 
bond formation. [32] 
 
For compounds containing only carbon and hydrogen atoms, the index of hydrogen deficiency is 
easily obtained by simple comparison of formulas. On the other hand, for more complex compounds 
containing not only carbon and hydrogen atoms, but also nitrogen, oxygen, sulphur, phosphate, silicon 
or halogen, a mathematical equation is more appropriate. For a compound with the generalized 
formula IIIγIII δIV, the index of hydrogen deficiency can be calculated as follows: [32] 
 
 
      122  IIIIIVIndex  [32] 
 
 
 is any monovalent atom (e.g. H, D, halogen),  is any bivalent atom (e.g. O, S), γ is any trivalent 
atom (e.g. N, P) and δ is any tetravalent atom (e.g. C, Si). The number of atoms within each group is 
represented by the numerals I-IV. Although molecular formulas provide a great deal of information 
about a compound, they are not sufficient for structure elucidation. Several isomers are possible for 
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the same molecular formula, thus, different spectrometric techniques (e.g. NMR, MS) need to be 
carried out in order to get the definite structure of a compound under investigation. [32] 
 
 
 
15. NMR Spectrometry 
 
 
15.1 Function 
 
NMR stands for nuclear magnetic resonance and is considered to be a type of absorption spectrometry 
(much like IR and UV). In its simplest form, NMR can be explained as a sample’s characteristic 
absorption of radiofrequencies in the presence of an external magnetic field, which yields an NMR 
spectrum that can be used to determine the chemical environment of the sample. This powerful tool is 
usually used in conjunction with other spectrometric equipment in order to identify the exact structure 
of organic compounds. [32]
 
 
 
15.2 Magnetic properties of nuclei 
 
Nuclei, as is well known, consist of both protons and neutrons, and thus, carry a net positive charge. 
When placed in an external magnetic field, these positive charges give some nuclei the magnetic 
ability to “spin”, meaning that nuclei will spin on their own axes. Magnetic dipoles are generated 
along the axis of every nucleus as a result of this magnetic property (Figure 15.1). [32] 
 
 
 
Figure 15.1  Magnetic dipole of a proton in an external magnetic field 
 
 
 
 
 
Source: http://www.mikepuddephat.com/Page/1603/Principles-of-magnetic-resonance-imaging 
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An important property of nuclei regarding the ability to ”spin”, is their quantum spin number, I. 
Quantum spin numbers are given in values of 0, 
1
/2, 1, 
3
/2, 2, 
5
/2, 3, and so on. Two different examples, 
but which are equally worth mentioning, are the 
1
H and the 
13
C nuclei. Both of these nuclei have 
quantum spin numbers of 
1
/2, meaning that they have a uniform, spherical charge distribution and that 
the nuclei can assume two separate orientations when placed in a magnetic field. The number of 
orientations a given nuclei may have in a magnetic field, can be determined by the formula 2I + 1, 
where I is of course the quantum spin number of the nuclei in question. [32]
 
 
Many other nuclei have quantum spin numbers of 
1
/2, e.g. 
3
H, 
15
N, 
19
F and 
31
P, but still the most widely 
used nuclei in NMR spectrometry are the nuclei 
1
H and 
13
C. [32] Both 
1
H and 
13
C NMR will be 
described next. 
 
 
15.3 
1
H NMR 
 
In a magnetic field, protons arrange themselves in two energy levels, with the lower energy level 
containing the highest amount of protons. Energy in the form of radiofrequency is applied to create a 
change in the population of these energy levels. Radiofrequency is given in units of megahertz (MHz). 
1
H spectra are normally recorded by the use of 300 MHz instruments. When the protons resonate with 
the applied radiofrequency, they absorb energy, thus, the lower energy protons are raised to a higher 
energy state. [32]
 
 
15.3.1 Spectrometers 
 
A spectrum can be recorded in two ways depending on the type of spectrometer; either by continuous-
wave spectrometer or by pulsed Fourier transform spectrometer. The continuous-wave spectrometer 
irradiates the sample by sweeping through the frequency range necessary to yield resonance. The 
resulting spectrum thus presents the absorption of energy as a function of frequency. The pulsed 
spectrometer irradiates the sample with a frequency range sufficiently large enough to yield resonance 
in all the nuclei at the same time. A detector collects the absorbed energy which is radiated by the 
nuclei as they return to their ground state. The information is thus available as absorption of energy as 
a function of time, which is useless in means of determining the sample’s structure. A Fourier 
transformation (a mathematical process) is therefore needed to convert the information to an 
interpretable spectrum which displays absorption of energy as a function of frequency. [32]
 
 
The continuous-wave spectrometer has several disadvantages such as low sensitivity with both limited 
amount of sample and with nuclei of low natural abundance, each scan takes more than a few minutes 
and repeated scanning does either nothing or very little to improve the signal/noise ratio. For these 
reasons, the continuous-wave spectrometer has been greatly exceeded by pulsed Fourier transform 
spectrometer. Since protons return to their ground state in a matter of seconds or less than a second, 
pulses can be repeated rapidly. Also repeated pulses lead to signal accumulation, thus improving the 
signal/noise ratio. [32] 
 
15.3.2 The proton spectrum 
 
A proton spectrum is displayed as a series of peaks at different frequencies and with different 
intensities (Figure 15.2). The area under each peak is proportional to the number of protons it 
represents, thus, by means of integration; it is possible to identify exactly how many protons are 
present in the compound under investigation. This invaluable information can be used to decipher the 
molecular formula of the compound, to discover chemically equivalent protons and to assess the purity 
of the sample. [32] 
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Figure 15.2 Ethyl acetate 
1
H NMR spectrum 
 
 
 
Source: http://www.chem2.bham.ac.uk/schools/ethyl-acetate-1h.htm 
 
 
 
15.3.3 “Shielding” and “deshielding” 
 
Every proton in a molecule is shielded by its electron cloud. The density of this electron cloud is 
different for protons in dissimilar chemical surroundings. These differences determine the position of 
each peak in a proton spectrum. The peaks are said to have different chemical shift positions. 
Chemical shift is described as the absorption position of a given NMR active nuclei relative to the 
absorption position of a reference nucleus. On the other hand, protons in similar chemical 
surroundings will have similar or identical chemical shifts. Thus, the peaks enable us to detect 
equivalent protons and to distinguish between non-equivalent protons. [32] 
 
In proton NMR, the most widely used reference compound is tetramethylsilane (Figure 15.3). 
Tetramethylsilane (TMS) yields a single and sharp absorption peak, and the protons are one of the 
most shielded protons in organic compounds. The absorption peak of TMS is assigned zero and placed 
at the right end of the NMR spectrum, thus, frequency increases from right to left. Absorption peaks to 
the right of the spectrum are termed “shielded” while absorption peaks to the left are termed 
"deshielded". This is in accordance with the fact that the reference compound, which contains one of 
the most shielded group of protons present in organic compounds, is placed at the right end of the 
spectrum. [32]
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Figure 15.3 Tetramethylsilane 
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15.3.4 
1
H NMR scale 
 
The NMR scale can be set to Hz and parts per million (ppm), which is a dimensionless unit. For 
reasons explained below, the NMR scale is generally set to ppm. If a 300 MHz spectrometer and a 600 
MHz spectrometer is used on the same sample, and the NMR scale is set to Hz, the absorption peak of 
a given proton in the sample will appear at a frequency in the 300 MHz spectrometer which is 
different from the frequency in the 600 MHz spectrometer. Alternatively, if the NMR scale is set to 
ppm, the absorption peak will appear on the same place. While Hz is dependent on the frequency of 
the operational spectrometer, ppm is not, thus, it is more practical to use this dimensionless unit for 
comparison purposes. [32] 
 
 
15.4 
13
C NMR 
 
As mentioned earlier, the 
13
C nucleus has a quantum spin number of 
1
/2, same as the 
1
H nucleus. The 
overall sensitivity of 
13
C compared to 
1
H, though, is only 1/5700 (i.e. approximately 6000 times less 
sensitive). The low overall sensitivity of the 
13
C nucleus is due to the combination of its low natural 
abundance compared to that of the 
12
C nucleus (1.1 %) and the low sensitivity compared to that of the 
1
H nucleus (1.6 %). [32] 
 
If the continuous-wave spectrometer is operated on 
13
C nuclei, the investigation will be both time-
consuming and require a large amount of sample. Therefore, the development of the pulsed Fourier 
transform spectrometer has led to a marked increase in the study of 
13
C. In addition, analysis of 
13
C 
and 
1
H spectra on the same sample provides useful information that can be used to either confirm or 
disprove the presence of certain functional groups. [32] 
 
15.4.1 Addressing coupling challenges 
 
Whereas 
13
C does not couple to 
1
H in 
1
H NMR spectra, coupling between 
1
H and 
13
C does occur in 
13
C 
NMR spectra. This means, in practical terms, that 
13
C NMR spectra show complex assemblies of 
absorption peaks, depending on the size of the compound under investigation, which are almost 
impossible to interpret. Coupling can be described as two NMR active nuclei, in different chemical 
surroundings, having a mutual effect on the “spin” of each other through intervening electrons. This 
mutual effect is made visible in NMR spectra through splitting of absorption peaks. For this reason, 
coupling complicates NMR spectra. Nevertheless, splitting can be avoided by irradiation of the 
1
H 
nuclei which decouples 
1
H nuclei from 
13
C nuclei, thus, the absorption peaks appear as singlets with 
each peak corresponding to single or chemically equivalent 13C nuclei. This type of spectrum is called 
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proton-decoupled 
13
C spectrum, and is the most commonly employed spectrum for the study of 
13
C 
(Figure 15.4). [32] 
 
 
 
Figure 15.4 Proton-decoupled 
13
C spectrum of ethyl acetate 
 
 
 
Source: http://chemwiki.ucdavis.edu/Organic_Chemistry/Organic_Chemistry_With_a_Biological_ 
 Emphasis/Chapter__5%3A_Structure_Determination_II/Section_6%3A_13C-NMR_ 
 spectroscopy 
 
 
 
15.4.2 
13
C NMR scale 
 
Just like for 
1
H, the NMR scale for 
13
C is generally set to units of ppm. The range of the chemical 
shifts, however, is about 220 ppm from the 
13
C nuclei in TMS to the left end of the spectrum. 
Absorption peaks rarely overlap due to the wide chemical shift range and the sharpness of each peak. 
[32] 
 
15.4.3 Absorption peaks 
 
While integration of absorption peaks in 
1
H NMR spectra yields an area that is proportional to the 
number of protons it represents, the same cannot be said about the absorption peaks in 
13
C NMR 
spectra. The peak intensities are affected by additional factors which render the area under each peak 
impossible to compare to one another. [32] 
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15.5 DEPT spectrum 
 
This is a popular technique within 
13
C NMR spectrometry which utilizes the differences in coupling 
constants between 
1
H and 
13
C in methine (-CH), methylene (-CH2) and methyl (-CH3) groups to 
generate an NMR spectrum that can be used to tell apart the different groups. In addition, this 
technique is more sensitive than the regular 
13
C NMR method. Thus, DEPT (Distortion Enhancement 
by Polarization Transfer) has become routine in many laboratories when NMR experiments are 
required. [32] 
Two separate spectrums can be produced through the use of DEPT depending on the angle of the 
pulsed radiofrequency, which is set to either 90° or 135°. The differences between the spectra is that in 
the 90° pulse sequence only 
13
C nuclei in CH groups are detected, meanwhile in the 135° pulse 
sequence all of the 
13
C nuclei are shown (except for quaternary carbons), but the CH3 and CH carbons 
are phased up, while the CH2 carbons are phased down. It is well worth mentioning that protons 
attached to other atoms (O, N, S, Si and P) are obviously not recorded, thus, there will be a difference 
in the number of protons in the DEPT spectrum and the 
1
H spectrum if such groups are present in the 
compound under investigation. [32]
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16. Solvents 
 
 
16.1 Solvents in both isolation and structure determination 
 
Many types of solvents were utilized in the isolation process. Most of which were organic solvents. 
Solvents were also mixed at different ratios in order to achieve a variety of solvent, eluent and 
developing systems with differing polarities. Only two types of solvents were employed in the 
structure determination, methanol-d4 in NMR and regular methanol in MS (Table 16.1). 
 
 
 
Table 16.1 Solvents from both the isolation and the identification of 
compounds 
 
Solvent Supplier 
Methanol (MeOH) Jiangsu Qiangsheng Chemical Co., Ltd  
Trichloromethane (CHCl3) Sinopharm Chemical Reagent Co., Ltd 
Dichloromethane (CH2Cl2) Shanghai Desheng Chemical Co., Ltd 
Ethyl acetate (EtOAc) Shanghai Zaituo Trade Co., Ltd 
Water (H2O) Shanghai Fudanyuan Purified Water Co., Ltd 
Ethanol (EtOH) Changshu Yangyuan Chemical Co., Ltd 
Sulphuric acid (H2SO4) Sinopharm Chemical Reagent Co., Ltd 
Formic acid (HCOOH) 40 E. Main St., Newark, DE 19711, USA 
Methanol-d4 (CD3OD) Cambridge Isotope Laboratories Inc. 
 
 
 
17. Materials 
 
 
17.1 Materials from the isolation process 
 
In order to purify a range of extracts and fractions, many chromatographic techniques need to be 
employed. The entire isolation process required different forms of low-pressure column 
chromatography and planar liquid chromatography. In addition to chromatographic materials, vanillin 
powder was necessary for the preparation of spray reagent and filter paper was utilized in gravity 
filtering (Table 17.1).  
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Table 17.1 Materials from the isolation of compounds 
 
Material Thickness 
(mm) 
Particle size 
(µm) 
Dimension  
(cm) 
Supplier 
Silica gel - 100-200 - Huiyou Silica Gel Development 
Co., Ltd 
Sephadex LH-20 - 40-70 - GE Healthcare Bio-Sciences AB 
TLC plate 0.15-0.20 10-40 5×20 Yantai Jiangyou Silica Gel 
Development Co., Ltd 
PTLC plate 0.4-0.5 10-40 20×20 Yantai Jiangyou Silica Gel 
Development Co., Ltd 
Vanillin powder - - - Sinopharm Chemical Reagent 
Co., Ltd 
Filter paper - - 11 Hangzhou Special Paper Co., Ltd 
 
 
 
18. Equipment 
 
 
18.1 Equipment in both isolation and structure determination 
 
Specific equipment was required in order to purify extracts and fractions and to analyze the isolated 
compounds. Rotary evaporator and UV lamp were used throughout the isolation process. Purified 
compounds were made ready for NMR and MS analysis by the use of a micropipette, NMR tubes and 
microcentrifuge tubes (Table 18.1). 
 
 
 
Table 18.1 Equipment from both the isolation and the identification of 
compounds 
 
Equipment Supplier 
Rotary evaporator Shanghai SENCO Technology Co., Ltd 
Automatic fraction collector Shanghai Qingpu-Huxi Instruments Factory: BSZ-100  
UV lamp for TLC WFH 203 Shanghai Jingke Industrial Co., Ltd 
UV lamp for PTLC WFH 203 Shanghai Jingke Industrial Co., Ltd 
Micropipette, 20-200 µL Axygen, Inc 
NMR tubes, 5 mm o.d. NORELL, Inc 
Microcentrifuge tubes, 1.5 mL Axygen, Inc 
NMR spectrometer Bruker Avance 600 
Mass spectrometer Agilent LC/MSD Trap XCT 
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19. Development of TLC plates 
 
 
19.1 Use of TLC 
 
TLC was performed continuously throughout the isolation process. Regardless of what type of sample 
was under investigation; that is raw material, chromatographic fractions, pooled fractions or purified 
compounds, TLC was performed before and after every step. 
 
 
19.2 Procedure 
 
With a grey pencil and a ruler, TLC plates were marked with a fine line 6 mm above the bottom. A 
grey pencil was also used to draw small, fine circles on the line approximately 5 mm from one 
another. The outermost circles were drawn about 1 cm from the edges. The TLC plates were cut into 
appropriate sizes by the use of a scalpel. Thin capillary tubes were used to spot fractions on their 
respective circles. After a spot was made, the thin capillary tube was immersed in MeOH which was 
subsequently absorbed by a piece of toilet paper. This was done at least three times between each spot 
that was made to avoid contamination between fractions. A single TLC plate was used for as little as 
one or as many as twenty fractions at a time (Figure 19.1). 
 
 
 
Figure 19.1 TLC plate before development 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
samples 
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The plates were gently dried with a hairdryer immediately after the last spot was made. By the use of a 
large pair of tweezers, the plates were picked up and placed in a small tank saturated with a solvent of 
a certain composition. The tanks were filled with solvent about 2-3 mm in height. The plates were left 
to develop until the solvent front had almost reached the top, at which point the plates were taken out 
and gently dried with a hairdryer (Figure 19.2). 
 
 
 
Figure 19.2 TLC plate after development  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After development, the separated compounds were detected by the use of UV-light, molecular iodine 
or a spray reagent, or by a combination of these. The detection methods mainly performed were UV 
and spray detection. Routinely, the plates were first observed under UV-light set at 254 nm. The 
largest and strongest spots were gently circled with a grey pencil, a spray reagent was added, and 
finally the plates were heated on a cooking plate until either colouration was observed or heating was 
finished. 
 
 
 
20. Isolation of compounds from Fraction 1 
 
 
20.1 The isolation process 
 
Fraction 1, Fraction 2 and Fraction 3 were dealt with in a sequential manner, meaning that compounds 
were isolated from Fraction 1 before commencing on Fraction 2 and so on. The isolation process 
comprised a variety of chromatographic techniques, each performed several times throughout the 
isolation process. Examples are low-pressure column chromatography and planar liquid 
chromatography. The first chromatographic technique performed was silica gel column 
chromatography. Isolation of compounds from Fraction 1 required all of the chromatographic 
techniques that would be performed, thus, when isolating compounds from Fraction 2 and Fraction 3, 
the same chromatographic techniques were employed. All the isolation and purification steps carried 
out on Fraction 1 are presented in Figure 25.1. 
separated 
compounds 
solvent front 
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20.2 Prior to silica gel column chromatography 
 
Fraction 1 was initially dry in an evaporating dish. As best as possible, a spatula was used to scrape off 
the dried fraction and transfer it to a clean, pre-weighed evaporating dish. Fraction 1 was calculated to 
weigh about 4 g. A mixture of dichloromethane (CH2Cl2) and methanol (MeOH) in a 10:1 ratio was 
added in enough quantities to dissolve Fraction 1 entirely. About 4.5 g silica gel was weighed and 
poured into the evaporating dish as well. Fraction 1 was left in a fume cupboard to dry off, thus, 
allowing dissolved components to adsorb onto the silica gel particles.  
 
 
20.3 Preparing the silica gel column 
 
To start with, the column was washed with MeOH. The silica gel column chromatography apparatus 
was then assembled. Approximately 120 g of silica gel, which is equal to 30 times the weight of 
Fraction 1, was weighed and transferred to the column. When all of the silica gel had been transferred, 
the column was dismounted and the tip of the column was gently hit against a soft, rubbery surface to 
compact the silica particles and release air bubbles within the adsorbent. The column was reattached to 
the rest of the apparatus and Fraction 1, which had adsorbed onto the silica gel particles in the 
evaporating dish, was transferred to the column by the use of a funnel and a spatula. Gentle taps on the 
side of the column made the sample more compact. Another layer of silica gel was added, just enough 
to cover the mixture of compounds. The column was tapped gently on the side one last time. A piece 
of cotton was placed on top of the last silica gel layer to protect the mixture of compounds (Figure 
20.1). 
 
 
 
Figure 20.1 Prepared silica gel column 
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20.4 Silica gel column chromatography 
 
An eluent system consisting of a mixture of CHCl3 and MeOH in a 30:1 ratio was first employed to 
separate the components in Fraction 1. Fractions of approximately 75 mL were collected throughout 
the silica gel column chromatography. Ten fractions were collected initially, wherefrom fractions 1 
through 4 were pooled and fractions 8 through 10 were pooled. Thus, a total of five fractions were 
collected with this 30:1 eluent system. 
 
CHCl3 and MeOH were used throughout the silica gel column chromatography, but at different ratios. 
After the first eluent system, an eluent system of 25:1 was employed. Initially, 14 fractions were 
collected, wherefrom fractions 11 through 16 were pooled and fractions 17 through 24 were pooled. 
Thus, a total of two fractions were collected with this 25:1 eluent system. 
 
A 20:1 eluent system followed. Seven fractions were collected initially and all of them were pooled. 
Thus, only one fraction was collected with this 20:1 eluent system. Interestingly, this fraction yielded a 
yellow colour on a TLC plate after spray detection followed by heating on a cooking plate. Thus, 
fraction 25-31 was set aside in order to further purify the mixture by polysaccharide size-exclusion 
chromatography. 
 
Silica gel column chromatography was continued with a 15:1 eluent system. Six fractions were 
collected initially, wherefrom fractions 32 through 34 were pooled and fractions 35 through 37 were 
pooled. Thus, a total of two fractions were collected with this 15:1 eluent system.  
 
A final eluent system of 10:1 was employed in the silica gel column chromatography. Initially, five 
fractions were collected, wherefrom fractions 38 through 41 were pooled. Thus, a total of two 
fractions were collected with this 10:1 eluent system. Fraction 38-41 gave several spots on a TLC 
plate both under UV light and after spray detection followed by heating. Therefore, polysaccharide 
size-exclusion chromatography was also performed on this fraction. 
 
 
20.5  1
st
 polysaccharide size-exclusion chromatography 
 
Fraction 25-31 from the silica gel column chromatography was transferred to an Erlenmeyer bulb and 
the solvent was evaporated through the use of a rotary evaporator. Just enough MeOH was added to 
dissolve the dried fraction completely. Fraction 25-31 was then added to a prepared Sephadex LH-20 
column with MeOH as the mobile phase.  
 
20.5.1 Transfer of fraction 25-31 to the Sephadex LH-20 column 
 
MeOH was eluted until it reached the bed of the Sephadex LH-20 particles. Fraction 25-31 was 
transferred to the column with a Pasteur pipette by slowly pressing out the sample in a circular motion 
along the inside of the column just over the bed of the Sephadex LH-20 particles. Such a transfer 
ensures an even distribution of components and, thus, a better separation. There was still sample left in 
the Erlenmeyer bulb, but a second Pasteur pipette with Fraction 25-31 was not added before the 
previous transfer had reached the bed of the Sephadex LH-20 particles. The rest of Fraction 25-31 and 
three Pasteur pipette washes of the Erlenmeyer bulb were transferred to the column in the same 
manner. When Fraction 25-31 had travelled sufficiently down the column, larger quantities of MeOH 
were added. MeOH was continually added to the column until enough fractions were collected. 
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20.5.2 Collecting fractions 
 
The tip of the Sephadex LH-20 column was connected to an automatic fraction collector right before 
the compounds were about to elute. The automatic fraction collector was set on an interval of 800 
seconds with fractions being collected in test tubes. Rate of elution was less than 1 drop per second. 
Initially, thirty-eight fractions were collected, wherefrom fractions 1 through 21 were pooled, fractions 
22 through 27 were pooled and fractions 28 through 38 were pooled. Thus, a total of three fractions 
were collected in the 1
st
 polysaccharide size-exclusion chromatography. Fraction 22-27 yielded two 
distinct spots both under UV-light and after spray detection followed by heating. The weight of 
fraction 22-27, however, was considered too low to be further purified by a simple chromatographic 
technique.  
 
 
20.6 2
nd
 polysaccharide size-exclusion chromatography 
 
Fraction 38-41 from the silica gel column chromatography was dried, dissolved and transferred to a 
prepared Sephadex LH-20 column in the same way as done in the 1
st
 polysaccharide size-exclusion 
chromatography. The tip of the Sephadex LH-20 column was connected to an automatic fraction 
collector right before the compounds were about to elute. The automatic fraction collector was set at 
an interval of 500 seconds with fractions being collected in test tubes. Rate of elution was 
approximately 1 drop per second. Initially, one hundred and five fractions were collected, wherefrom 
fractions 1 through 4 were pooled, fractions 5 through 11 were pooled, fractions 12 through 35 were 
pooled, fractions 36 through 39 were pooled, fractions 40 through 51 were pooled, fractions 52 
through 81 were pooled, fractions 82 through 90 were pooled and fractions 91 through 105 were 
pooled. Thus, a total of eight fractions were collected in the 2
nd
 polysaccharide size-exclusion 
chromatography. 
 
20.6.1 Evaluation of collected fractions 
 
Fraction 5-11 yielded an almost single purple spot under UV-light which was not visible after spray 
detection followed by heating. A PTLC was performed on fraction 5-11 to achieve purer results. 
Fraction 40-51 showed two separate yellow spots after spray detection followed by heating, thus, a 
PTLC was performed on this fraction as well. Fraction 91-105 yielded a single, clear yellow spot after 
spray detection followed by heating. The weight of this fraction was 69.1 mg. Fraction 91-105 was 
considered pure enough for structure determination and was therefore sent to another laboratory at the 
Department of Natural Medicinal Chemistry for NMR and MS analysis. Fraction 91-105 was given 
the name CAP-1. Every fraction that was considered pure enough for structure determination was 
given the name CAP followed by a number. CAP is an acronym for Carlos Abies pindrow. The 
numbers were given to seemingly pure fractions in a chronological order as they were being collected 
in the isolation process.  
 
 
20.7 1
st
 silica adsorbent PTLC 
 
Fraction 5-11 from the 2
nd
 polysaccharide size-exclusion chromatography was transferred to a pre-
weighed Erlenmeyer bulb and the solvent was evaporated by the use of a rotary evaporator. The 
weight of the fraction was calculated to be 220.4 mg. Just enough MeOH was added to dissolve the 
dry fraction entirely. Fraction 5-11 was distributed on two PTLC plates and developed in the same 
twin trough chamber. 
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20.7.1 Development of PTLC plates 
 
Fine lines about 1.5 cm above the bottom of the PTLC plates were marked with a grey pencil. Fraction 
5-11 was evenly distributed along the grey pencil lines with a thick capillary tube. Approximately 1 
cm on both sides of the PTLC plates were not covered with sample to avoid “edge effects” (Figure 
20.2). 
 
 
 
Figure 20.2 PTLC plate before development  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A twin trough chamber was filled with 50 mL of a 20:1 (CHCl3:MeOH) solvent system. Immediately 
before the PTLC plates were placed in the twin trough chamber, they were gently dried with a 
hairdryer to make sure that both MeOH and water particles were removed before development, since 
both can affect separation. Development was finished when the solvent front had reached the top of 
the plates (Figure 20.3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
sample 
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Figure 20.3 PTLC plate after development 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20.7.2 Desorption of compound from silica adsorbent 
 
UV-light was used to visualize the compound of interest adsorbed onto the PTLC plates. Fine 
markings around the compound were made with a grey pencil. Silica adsorbent was gently scraped off 
the glass backing plates and onto a paper of A4 format with a spatula. Silica adsorbent particles from 
each PTLC plate were poured into separate 50 mL beakers and crushed into finer particles. Desorption 
was enabled by the use of a 3:1 (CH2Cl2:MeOH) solvent system at a volume about double of that 
occupied by the silica adsorbent particles. Two simple assemblies, each consisting of a 100 mL 
Erlenmeyer flask, a funnel and a folded filter paper, were used for gravity filtering of each beaker. The 
extracts in the beakers were transferred onto the filter papers with a Pasteur pipette. Desorption was 
performed three times in total. The final extracts were combined and purity assessed by TLC. The 
compound was purple under UV-light, but no colour was visible after spray detection followed by 
heating. Weight of the isolated compound was calculated to be 149.9 mg. This compound was given 
the name CAP-4. 
 
 
20.8 2
nd
 silica adsorbent PTLC 
 
Fraction 40-51 from the 2
nd
 polysaccharide size-exclusion chromatography was dried, dissolved and 
developed in the same way as done in the 1
st
 silica adsorbent PTLC. Two PTLC plates were evenly 
distributed with fraction 40-51 and placed in a twin trough chamber filled with 50 mL of a 6:1 
(CHCl3:MeOH) developing solvent. When development was finished, two separate bands could be 
seen on each plate under UV-light. Desorption of these compounds was performed in the same way as 
done in the 1
st
 silica adsorbent PTLC. 
 
 
separated 
compounds 
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20.8.1 Assessment of compounds 
 
The highest band (i.e. the one with the highest Rf value) on the PTLC plates was weighed after 
desorption. Calculated weight was found to be 11.7 mg. This compound was given the name CAP-2. 
The lower band (i.e. the one with the lowest Rf value) on the PTLC plates seemed less pure, thus, a 
polysaccharide size-exclusion chromatography was performed on this extract. 
 
 
20.9 3
rd
 polysaccharide size-exclusion chromatography 
 
A polysaccharide size-exclusion chromatography was performed on the extract with lowest Rf value 
from the 2
nd
 silica adsorbent PTLC. The extract was dried, dissolved and transferred to a small, self-
prepared Sephadex LH-20 column in the same way as that done in previous polysaccharide size-
exclusion chromatography. Fractions were collected in 50 mL beakers. Fractions were collected right 
before the compounds were about to elute. Each fraction was approximately a volume of 50 mL. 
 
20.9.1 Preparing the Sephadex LH-20 column 
 
Sephadex LH-20 particles had already been added to the column, but it was all dried out. Elution was 
hindered by turning the stopcock at a 90° angle to the column. A chromatography reservoir was 
attached to the column and the column was filled with MeOH until approximately ¼ of the 
chromatography reservoir contained MeOH. A ground stopper was attached to the chromatography 
reservoir, the column was dismounted from the rest of the apparatus and everything was turned upside 
down repeatedly until all the Sephadex LH-20 particles were wet. This made the Sephadex LH-20 
particles pack neatly in the column. The column was reattached to the rest of the apparatus and 
subsequent elution made the Sephadex LH-20 particles settle to a compact gel layer. 
 
20.9.2 Collected fractions 
 
Ten fractions were collected initially, wherefrom fractions 1 and 2 were pooled, fractions 3 through 7 
were pooled and fractions 8 through 10 were pooled. Thus, a total of three fractions were collected in 
the 3
rd
 polysaccharide size-exclusion chromatography. Fraction 3-7 gave a single, purple spot under 
UV-light. The weight of this fraction was calculated to be 75.7 mg. Fraction 3-7 was given the name 
CAP-3.  
 
 
 
21. Isolation of compounds from Fraction 2 
 
 
21.1 Purification of Fraction 2 
 
When the isolation process on Fraction 1 was finished, purification was continued on Fraction 2. Only 
two chromatographic steps were employed on Fraction 2. Thus, isolation of compounds from Fraction 
2 took considerably less time compared to isolation of compounds from Fraction 1. Both 
polysaccharide size-exclusion chromatography and silica adsorbent PTLC was performed. The 
isolation process carried out on Fraction 2 is presented in Figure 26.1. 
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21.2 Polysaccharide size-exclusion chromatography 
 
A polysaccharide size-exclusion chromatography was performed on Fraction 2 from the initial 
extraction and isolation carried out by Dr. Li Yong-Li. Fraction 2 was dried, dissolved and transferred 
to a prepared Sephadex LH-20 column in the same way as done in previous size-exclusion 
chromatography. The tip of the column was connected to an automatic fraction collector right before 
the compounds were about to elute. The automatic fraction collector was set at an interval of 600 
seconds with fractions being collected in test tubes. Rate of elution was approximately 1 drop per 
second. Initially, fifty-one fractions were collected, wherefrom fractions 1 through 6 were pooled, 
fractions 7 through 15 were pooled, fractions 18 through 20 were pooled and fractions 21 through 50 
were pooled. Thus, a total of seven fractions were collected in this polysaccharide size-exclusion 
chromatography. Silica adsorbent PTLC was performed on fraction 7-15. Fraction 51 was collected in 
a 250 mL Erlenmeyer flask to make sure that all of the compounds had eluted. Fraction 51 reached a 
final volume of 150 mL. 
 
 
21.3 Silica adsorbent PTLC 
 
Fraction 7-15 from the polysaccharide size-exclusion chromatography was dried, dissolved and 
developed in the same way as done in previous silica adsorbent PTLCs. Before development, fraction 
7-15 was calculated to weigh 130.1 mg, thus, two PTLC plates were employed. Both PTLC plates 
were evenly distributed with fraction 7-15 and placed in a twin trough chamber filled with 50 mL of a 
3:1 (CHCl3:MeOH) developing system and 5 mL HCOOH, which served to improve separation. When 
development was finished, desorption was performed in the same way as done in previous silica 
adsorbent PTLCs by the use of a 2:1 (CHCl3:MeOH) solvent system. The compound was purple under 
UV-light and yellow after spray detection followed by heating. Calculated weight of the compound 
was found to be 85.3 mg. This compound was given the name CAP-5.  
 
 
 
22. Isolation of compounds from Fraction 3 
 
 
22.1 Final isolation steps 
 
Fraction 3 was the last major fraction to be purified. Both column chromatography and planar 
chromatography were employed. Fraction 3 required significantly more isolation steps compared to 
Fraction 2. The first chromatographic technique to be performed on Fraction 3 was polysaccharide 
size-exclusion chromatography. All of the isolation and purification steps carried out on Fraction 3 are 
presented in Figure 27.1. 
 
 
22.2 1
st
 polysaccharide size-exclusion chromatography 
 
Polysaccharide size-exclusion chromatography was employed on Fraction 3 from the initial extraction 
and isolation carried out by Dr. Li Yong-Li. Fraction 3 was dried, dissolved and transferred to a 
prepared Sephadex LH-20 column in the same way as done in previous size-exclusion 
chromatography. The tip of the column was connected to an automatic fraction collector right before 
the compounds were about to elute. The automatic fraction collector was set at an interval of 600 
seconds with fractions being collected in test tubes. Rate of elution was approximately 1 drop per 
second. Forty-one fractions were collected initially, wherefrom fractions 1 through 4 were pooled, 
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fractions 5 through 19 were pooled, fractions 20 through 31 were pooled and fractions 32 through 41 
were pooled. Thus, a total of four fractions were collected in this 1
st
 polysaccharide size-exclusion 
chromatography. Silica gel column chromatography was performed on fraction 5-19 while silica 
adsorbent PTLC was performed on fraction 20-31. 
 
 
22.3 Silica gel column chromatography 
 
A silica gel column chromatography was performed on fraction 5-19 from the 1
st
 polysaccharide size-
exclusion chromatography. Fraction 5-19 was calculated to weigh 377.2 mg. Both the sample and the 
silica gel column were prepared in the same way as done in previous silica gel column 
chromatography, with the exceptions that half the column was filled with silica gel instead of 
approximately 30 times the weight of the sample and two teaspoons of silica gel were poured into the 
evaporating dish. Fractions of about 75 mL were collected throughout the silica gel column 
chromatography. 
 
22.3.1 Collecting fractions with a 10:1 eluent system 
 
A 10:1 (CH2Cl2:MeOH) eluent system was first employed to separate the compounds in fraction 5-19. 
Initially, ten fractions were collected, wherefrom fractions 1 through 3 were pooled, fractions 4 
through 7 were pooled and fractions 8 through 10 were pooled. Thus, a total of three fractions were 
collected with this 10:1 eluent system.  
 
22.3.2 Collecting fractions with a 5:1 eluent system 
 
A second and final eluent to be employed was a 5:1 (CH2Cl2:MeOH) eluent system. Six fractions were 
collected initially, wherefrom fractions 11 and 12 were pooled and fractions 13 through 16 were 
pooled. Thus, a total of two fractions were collected with this 5:1 eluent system. 
 
22.3.3 Further purification of fractions 
 
Fraction 4-7 was calculated to weigh 142.2 mg, thus, there was enough material to perform a silica 
adsorbent PTLC on this fraction. Fraction 8-10 was first pooled with fraction 11-12 and subsequently 
combined with the extract from the lowest band in the 2
nd
 silica adsorbent PTLC performed on fraction 
4-7. The resulting fraction was named fraction Low Rf + 8-12 and was further purified in a 
polysaccharide size-exclusion chromatography. 
 
 
22.4 1
st
 silica adsorbent PTLC 
 
Fraction 20-31 from the 1
st
 polysaccharide size-exclusion chromatography was dried, dissolved and 
developed in the same way as done in previous silica adsorbent PTLCs. Two PTLC plates were evenly 
distributed with fraction 20-31 and placed in a twin trough chamber filled with 50 mL of a 4:1 
(CHCl3:MeOH) developing system. Desorption was performed in the same way as done in previous 
silica adsorbent PTLCs by the use of a 2:1 (CHCl3:MeOH) solvent system. The compound was purple 
under UV-light and slight yellow after spray detection followed by heating. Weight of the compound 
was calculated to be 65.6 mg. This compound was given the name CAP-6.  
 
 
 
 
  Methods 
49 
 
22.5 2
nd
 silica adsorbent PTLC 
 
Fraction 4-7 from the silica gel column chromatography was dried, dissolved and developed in the 
same way as performed in previous silica adsorbent PTLCs. Two PTLC plates were evenly distributed 
with fraction 4-7 and placed in a twin trough chamber filled with 50 mL of a 3:1 (CHCl3:MeOH) 
developing system. Two separate bands could be seen on the PTLC plates under UV-light after 
development. Desorption of these compounds was performed in the same way as done in previous 
silica adsorbent PTLCs by the use of a 2:1 (CH2Cl2:MeOH) solvent system.  
 
22.5.1 Evaluation of compounds 
 
The highest band (i.e. the one with the highest Rf value) on the PTLC plates was weighed after 
desorption. The compound was purple under UV-light and strong yellow after spray detection 
followed by heating. Weight of the compound was calculated to be 23.0 mg. This compound was 
given the name CAP-7. On the basis of TLC results, the lower band (i.e. the one with the lowest Rf 
value) on the PTLC plates was combined with fractions 8-10 and 11-12 from the silica gel column 
chromatography after desorption. A polysaccharide size-exclusion was performed on this fraction. 
 
 
22.6 2
nd
 polysaccharide size-exclusion chromatography  
 
As explained earlier, a polysaccharide size-exclusion chromatography was performed on fraction Low 
Rf + 8-12, which is a combined fraction from both the 2
nd
 silica adsorbent PTLC and the silica gel 
column chromatography. Fraction Low Rf + 8-12 was dried, dissolved and transferred to a prepared 
Sephadex LH-20 column in the same way as done in previous polysaccharide size-exclusion 
chromatography. The tip of the column was connected to an automatic fraction collector right before 
the compounds were about to elute. The automatic fraction collector was set at an interval of 500 
seconds with fractions being collected in test tubes. Rate of elution was approximately 1 drop per 
second. Initially, nineteen fractions were collected, wherefrom fractions 1 through 3 were pooled, 
fractions 4 and 5 were pooled, fractions 6 through 10 were pooled, fractions 11 through 15 were 
pooled and fractions 16 through 19 were pooled. Thus, a total of five fractions were collected in this 
2
nd
 size-exclusion chromatography.  
 
22.6.1 Assessment of fractions 
 
Fraction 4-5 seemed to contain only one compound, which was purple under UV-light. Spray 
detection followed by heating yielded a yellow colour. Weight of the compound was calculated to be 
5.0 mg. This compound was given the name CAP-8. Final isolation step was silica adsorbent PTLC 
performed on fraction 11-15. 
 
 
22.7 3
rd
 silica adsorbent PTLC 
 
Fraction 11-15 from the 2
nd
 polysaccharide size-exclusion chromatography was dried, dissolved and 
developed in the same way as done in previous silica adsorbent PTLCs. Calculated weight of fraction 
11-15 was found to be only 29.3 mg. Such a small amount of sample is generally considered too low 
to be further purified by silica adsorbent PTLC. Nonetheless, an attempt to isolate one final compound 
in sufficient quantities for structure determination was done by the use of a single PTLC plate. The 
PTLC plate was evenly distributed with fraction 11-15 and placed in a twin trough chamber filled with 
50 mL of a 20:3.4:2.7 (EtOAc:MeOH:H2O) developing solvent. After development, desorption was 
performed in the same way as done in previous silica adsorbent PTLCs by the use of a 2:1 
(CHCl3:MeOH) solvent system. 
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22.7.1 Last isolated compound   
 
The last isolated compound was purple under UV-light and strong yellow after spray detection 
followed by heating. Weight was calculated to be 15.6 mg. This compound was given the name CAP-
9. 
 
 
 
23. NMR and MS analysis 
 
 
23.1 Preparing isolated compounds for NMR 
 
Isolated compounds deemed pure enough for structure determination were analyzed both by NMR and 
MS. In the case of NMR, a solvent without protons is employed to enable correct interpretation of 
absorption peaks on the resulting spectra. Compounds were almost completely dissolved with 0.6 mL 
of CD3OD. A micropipette was used to transfer the solutions to NMR tubes. Each NMR tube was 
named after the isolated compound and Dr. Li Yong-Li was in charge of transporting the samples to 
another laboratory at the Department of Natural Medicinal Chemistry for NMR analysis. 
 
 
23.2 Preparing isolated compounds for MS 
 
As explained in the section above, not all the amounts of the isolated compounds were dissolved by 
CD3OD, thus, residual amounts were used in MS. Since deuterated solvents are not needed for MS 
analysis, dilute solutions of the isolated compounds were made by the addition of MeOH. Solutions 
were considered to be dilute when they displayed fairly weak colouration. By the use of a 
micropipette, 0.5 mL of these dilute solutions were transferred to separate microcentrifuge tubes. Each 
microcentrifuge tube was named after the isolated compound and Dr. Li Yong-Li was in charge of 
transporting the samples to another laboratory at the Department of Natural Medicinal Chemistry for 
MS analysis.
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Results and discussion 
 
 
 
24. Prior work 
 
 
24.1 Initial steps 
 
Prior to my involvement, Dr. Li Yong-Li had dried and pulverized both branches and leaves from 
Abies pindrow. Pulverization was followed by a series of extraction steps and a final column 
chromatography (Figure 24.1). 
 
 
Figure 24.1 Initial extraction and isolation carried out by Dr. Li Yong-Li prior 
to my involvement in the purification process 
 
Collected plant 
 
 
Drying and pulverization  
 
         Extraction with EtOH 
 
EtOH extract 
 
          Partition with 
           CHCl3 
 
             CHCl3 phase is removed 
 
EtOH phase 
 
           Partition with 
           EtOAc 
 
              EtOH phase is removed 
 
    EtOAc phase     Partition with n-BuOH  
           Silica gel column  
               chromatography 
        EtOH phase 
        is removed  
          n-BuOH phase 
 
       Fraction 1      Fraction 2 Fraction 3 
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24.2 Initial extraction and partition 
 
After the plant had been dried and pulverized, Dr. Li Yong-Li proceeded with extraction by the use of 
different solvents. The pulverized branches and leaves were first extracted with EtOH. The solid mass 
left after initial extraction was removed. Compounds extracted with EtOH were subsequently 
partitioned with CHCl3. Purification was intended to continue on the EtOH phase, thus, the CHCl3 
phase was removed. Another partition with EtOAc was performed on the EtOH phase. This time the 
EtOH phase was removed, but purification was continued on both solvent phases. While the EtOH 
phase went through a final partition with n-BuOH, a silica gel column chromatography was performed 
on the EtOAc phase. 
 
 
24.3 Initial silica gel column chromatography 
 
As described above, Dr. Li Yong-Li performed a silica gel column chromatography on the EtOAc 
phase from the initial partition steps. This was the last isolation step performed prior to my 
involvement in the isolation process. The silica gel column chromatography generated three separate 
fractions, which I have chosen to name Fraction 1, Fraction 2 and Fraction 3. 
 
 
 
25. Purification of Fraction 1 
 
 
The entire range of simple chromatographic techniques was employed in the isolation of compounds 
from Fraction 1. Silica gel column chromatography was the first isolation step carried out on Fraction 
1. All of the isolation and purification steps are presented in Figure 25.1. 
 
 
 
26. Purification of Fraction 2 
 
 
Only two chromatographic steps were employed on Fraction 2. A polysaccharide size-exclusion 
chromatography was carried out first followed by a silica adsorbent PTLC. The isolation process 
carried out on Fraction 2 is presented in Figure 26.1.  
 
 
 
27. Purification of Fraction 3 
 
 
Isolation of compounds from Fraction 3 required the entire range of simple chromatographic 
techniques as well. A polysaccharide size-exclusion chromatography was the first chromatographic 
technique to be employed on Fraction 3. All of the isolation and purification steps are presented in 
Figure 27.1.  
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Figure 25.1 Isolation steps carried out on Fraction 1 including weights of 
fairly pure fractions 
 
 
Fraction 1 (4 g) 
 
                 Silica   Silica     Silica 
   Silica gel CC with a 30:1 eluent          gel CC       gel CC        gel CC   Silica gel CC with a 10:1 eluent 
   system (TCM:M)   with a 25:1 with a           with a 15:1           system (TCM:M) 
            eluent system    20:1 eluent  eluent system 
(TCM:M)           system      (TCM:M) 
             (TCM:M) 
 
 
   1-4    5      6       7    8-10  11-16 17-24   25-31    32-34  35-37         38-41  42 
 
1
st
 polysaccharide SEC with              2
nd
 polysaccharide 
        M as eluent       SEC with M as eluent 
 
 
 
 
1-21  22-27  28-38          1-4      5-11   12-35   36-39 40-51    52-81   82-90   91-105 
              (16.0 mg)                   (CAP-1, 
             69.1 mg) 
        1
st
 silica adsorbent PTLC with             2nd silica adsorbent PTLC with 
a 20:1 developing             a 6:1 developing 
           solvent (TCM:M)             solvent (TCM:M) 
 
 
 
 
  Purple colour       Low Rf    High Rf 
  under UV-light               (CAP-2, 11.7 mg)  
  (CAP-4, 149.9 mg)                  
                    3
rd
 polysaccharide SEC with 
                    M as eluent 
 
 
 
 
 
            1-2      3-7     8-10 
             (CAP-3, 
        75.7 mg) 
 
 
CC = column chromatography, TCM = trichloromethane, M = methanol, SEC = size-exclusion chromatography, 
PTLC = preparative thin layer chromatography, Rf = retardation factor. 
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Figure 26.1 Isolation steps carried out on Fraction 2 including weights of 
fairly pure fractions 
 
 
Fraction 2 
 
 
             Polysaccharide SEC 
             with M as eluent  
 
 
 
 
1-6 7-15   16    17 18-20   21-50    51 
         (130.1 mg)       (150 mL) 
 
 
           Silica adsorbent PTLC  
       with a 3:1 developing  
       solvent (TCM:M)  
       + 5 mL FA 
 
 
    Purple colour 
    under UV-light 
       (CAP-5, 85.3 mg) 
 
 
FA = formic acid. 
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Figure 27.1 Isolation steps carried out on Fraction 3 including weights of 
  fairly pure fractions 
 
Fraction 3 
 
 
              1st polysaccharide SEC 
              with M as eluent  
 
 
 
 
     1-4     5-19       20-31 32-41 
    
Silica gel CC  Silica gel CC              1
st
 silica adsorbent PTLC 
         with a 10:1   with a 5:1 eluent              with a 4:1 developing 
           eluent system   system (DCM:M)  solvent (TCM:M) 
          (DCM:M)      
 
 
 
    1-3     4-7   8-10        11-12   13-16   Purple colour 
         under UV-light 
   2
nd
 silica adsorbent            (CAP-6, 65.6 mg) 
       PTLC with a 3:1 
   developing solvent 
                  (TCM:M) 
 
 
   
  High Rf Low Rf      Low Rf + 8-12 
          (CAP-7, 23.0 mg) 
 
                  2nd polysaccharide SEC 
                   with M as eluent 
 
 
 
 
              1-3 4-5   6-10   11-15   16-19 
               (CAP-8, 5.0 mg) 
3
rd
 silica 
adsorbent PTLC 
with a 20:3.4:2.7 
developing 
solvent 
(EA:M:W) 
 
Purple under 
          under UV-light 
            (CAP-9, 15.6 mg) 
 
DCM = dichloromethane, EA = ethyl acetate, W = water. 
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28. Evaluation of fractions 
 
 
28.1 Fractions that were not further purified 
 
Collected fractions from every isolation step were evaluated with regards to purity and polarity. Some 
fractions were also evaluated with regards to weight. Majority of fractions were not further purified 
due to a number of reasons: too many compounds were present, compounds weighed too little to be 
further purified by a simple chromatographic technique, compounds had already been isolated, no 
compounds were present and/or polarity of compounds was too low or too high.  
 
 
28.2 Further purified fractions  
 
Fractions that were further purified displayed one or several desirable traits: compounds were of 
appropriate polarity, compounds weighed enough to be further purified by a simple chromatographic 
technique, no more than five compounds were present and/or compounds had not been isolated earlier 
in the isolation process. Purification of fractions continued until they were considered pure enough 
(i.e. only one compound was present) for structure elucidation.  
 
 
 
29. Compounds prepared for structure determination 
 
 
29.1 Pure fractions  
 
Fractions considered pure enough for structure determination were, as previously explained, given the 
name CAP followed by a number. Before preparing compounds for NMR and MS analysis, they were 
assessed in two different developing solvents to avoid seemingly “pure” spots resulting from 
compounds with matching Rf values. In addition to Rf values, calculated weights and the colour of 
every compound, both under UV-light and after spray detection, were recorded as well prior to NMR 
and MS analysis (Table 29.1). 
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Table 29.1 Characteristics of isolated compounds 
 
 
 
 
29.2 CAP-1 
 
CAP-1 was made visible through the use of UV-light and spray detection followed by heating. A 
single, clear yellow spot appeared on a TLC plate developed in a 5:1 (CHCl3:MeOH) developing 
system. Rf was calculated to be 0.68 and weight was calculated to be 69.1 mg. 
 
 
29.3 CAP-2 
 
CAP-2 was the only compound that was visible without the use of any detection method. A strong 
yellow spot appeared on a TLC plate developed in a 30:1 (CHCl3:MeOH) developing system. Rf was 
calculated to be 0.62 and weight was calculated to be 11.7 mg. 
 
 
29.4 CAP-3  
 
CAP-3 was visible both under UV-light and after spray detection followed by heating. A slight yellow 
spot appeared on a TLC plate developed in a 5:1 (CHCl3:MeOH) developing system. Rf was 
calculated to be 0.51 and weight was calculated to be 75.7 mg.  
 
 
29.5 CAP-4 
 
CAP-4 was made visible only under UV-light, where it was purple. No colour was visible after spray 
detection followed by heating. The compound was developed in a 20:1 (CHCl3:MeOH) developing 
system. In order to calculate Rf, the purple spot was gently circled with a grey pencil. Rf was 
calculated to be 0.54 and weight was calculated to be 149.9 mg. 
 
 
 
 
Compound Colour Developing solvent Rf Weight 
(mg) Under UV-light 
(254 nm) 
After spray 
detection 
No detection 
method 
CAP-1 Purple Clear yellow - 5:1 (CHCl3:MeOH) 0.68 69.1 
CAP-2 - - Strong yellow 30:1 (CHCl3:MeOH) 0.62 11.7 
CAP-3 Purple Slight yellow - 5:1 (CHCl3:MeOH) 0.51 75.7 
CAP-4 Purple No colour - 20:1 (CHCl3:MeOH) 0.54 149.9 
CAP-5 Purple Yellow - 3:1 (CHCl3:MeOH) 
+ 5 drops HCOOH 
0.59 85.3 
CAP-6 Purple Slight yellow - 3:1 (CHCl3:MeOH 0.63 65.6 
20:3.4:2.7 (EA:M:W) 0.75 
CAP-7 Purple Strong yellow - 3:1 (CHCl3:MeOH 0.63 23.0 
20:3.4:2.7 (EA:M:W) 0.75 
CAP-8 Purple Yellow - 20:3.4:2.7 (EA:M:W) 0.54 5.0 
CAP-9 Purple Strong yellow - 20:3.4:2.7 (EA:M:W) 0.56 15.6 
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29.6 CAP-5 
 
CAP-5 was made visible by the use of UV-light and spray detection followed by heating. A yellow 
spot appeared on a TLC plate developed in a 3:1 (CHCl3:MeOH) developing system added 5 drops of 
formic acid. Rf was calculated to be 0.59 and weight was calculated to be 85.3 mg. 
 
 
29.7 CAP-6 
 
CAP-6 was visible both under UV-light and after spray detection followed by heating. A slight yellow 
spot appeared both on a TLC plate developed in a 3:1 (CHCl3:MeOH) developing system and on a 
TLC plate developed in a 20:3.4:2.7 (EtOAc:MeOH:H2O) developing system. Rf was calculated to be 
0.63 in the former and 0.75 in the latter developing system. Weight was calculated to be 65.6 mg. 
 
 
29.8 CAP-7 
 
CAP-7 was made visible by the use of UV-light and spray detection followed by heating. This 
compound exhibited the exact same Rf values as CAP-6 in the same developing systems. Thus, CAP-7 
and CAP-6 were considered to be the same compound. However, CAP-7 was strong yellow after spray 
detection followed by heating and weight was calculated to be 23.0 mg. CAP-7 seemed purer than 
CAP-6, thus, only CAP-7 was sent to another laboratory at the Department of Natural Medicinal 
Chemistry for NMR and MS analysis.  
 
 
29.9 CAP-8 
 
CAP-8 was visible both under UV-light and after spray detection followed by heating. A yellow spot 
appeared on a TLC plate developed in a 20:3.4:2.7 (EtOAc:MeOH:H2O) developing system. Rf was 
calculated to be 0.54 and weight was calculated to be 5.0 mg. 
 
 
29.10 CAP-9 
 
CAP-9 was visible both under UV-light and after spray detection followed by heating. A strong yellow 
spot appeared on a TLC plate developed in a 20:3.4:2.7 (EtOAc:MeOH:H2O) developing system. Rf 
and weight were calculated to be 0.56 and 15.6 mg, respectively. 
 
 
 
30. Structure determination 
 
 
30.1 Employed techniques 
 
Both MS and NMR were employed in the structure determination of the different isolated compounds. 
MS was performed by electro spray ionisation and ion trap analysis. Compounds were analysed in 
both positive ion mode and negative ion mode, i.e. the molecular ions appeared as [M+Na]
+
 and [M-
H]
-
 on the MS spectra, respectively. Thus, molecular weights were easily obtained by MS. As for 
NMR, compounds were analysed both by 1H and 13C NMR. DEPT-135 spectra were also obtained. 
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Chemical shifts from NMR spectra were compared to published chemical shifts from previously 
isolated organic compounds. DEPT-135 spectra were used to detect dissimilar carbons and to confirm 
proposed structures. 
 
 
30.2 Structure elucidation of CAP-1 
 
MS analysis of CAP-1 yielded quasi-molecular ions at m/z: 747 [M+Na]
+
 and 723 [M-H]
-
 in the 
positive ion mode and negative ion mode, respectively (Figure 30.1). Thus, the molecular weight of 
CAP-1 was calculated to be 724 Da. 
 
 
 
Figure 30.1 MS spectra from CAP-1 
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30.2.1 Interpretation of 
1
H NMR spectra 
 
Two 
1
H NMR spectra from CAP-1 can be found between the last pages of this Master’s thesis 
(Supplementary material 1.1 and Supplementary material 1.2). One spectrum displays all the peaks 
yielded by the protons in CAP-1, while the other spectrum is a close-up of peaks yielded by the most 
deshielded protons in CAP-1. The former spectrum ranges from 8.0-0.5 ppm, while the latter ranges 
from 7.9-4.0 ppm. These NMR spectra were interpreted prior to comparison of chemical shifts with 
published chemical shifts from a previously isolated organic compound (Table 30.1). 
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Table 30.1 Interpretation of 
1
H NMR spectra from CAP-1 
 
ppm Multiplicity and 
coupling constant (Hz) 
No. of protons  Assignment 
7.79-7.76 Doublet, 9 2 Aromatics 
7.65-7.60 Doublet, 15 2 Aromatics 
7.54-7.52 Doublet, 6 2 Aromatics 
7.47-7.44 Doublet, 9 2 Aromatics 
7.04-7.01 Doublet, 9 2 Aromatics or alkenes 
6.83-6.80 Doublet, 9 2 Aromatics, alkenes or -
disubstituted aliphatics 
6.80-6.77 Doublet, 9 2 Aromatics, alkenes or -
disubstituted aliphatics 
6.43-6.38 Doublet, 15 1 Aromatic, alkene or -
disubstituted aliphatic 
6.34 Singlet 1 Aromatic, alkene or -
disubstituted aliphatic 
6.32-6.27 Doublet, 15 1 Aromatic, alkene or -
disubstituted aliphatic 
6.18 Singlet 1 Aromatic, alkene or -
disubstituted aliphatic 
5.76 Singlet ? Alkene(s) or -
disubstituted aliphatic(s) 
5.58 Singlet 1 Alkene or -
disubstituted aliphatic 
Approx. 5.00 Large, broad peak ? Alkene(s) or -
disubstituted aliphatic(s) 
4.21-4.17 Double doublet, 3, 9 1 -monosubstituted or -
disubstituted aliphatic 
Approx. 3.30 Large, thin peak ? -monosubstituted or -
disubstituted aliphatic(s) 
0.87-0.85 Doublet, 6 3 Methyl 
 
 
 
As can be deduced from Table 30.1, CAP-1 consists of at least twenty-one chemically dissimilar 
protons. If assumed that the question marks represent one proton each, a total of twenty-four 
chemically dissimilar protons are present in CAP-1. Protons bound to oxygen are not included, thus, 
the total number of protons is probably higher than twenty-four. Assignment of functional groups 
gives a strong reason to believe that CAP-1 consists of several aromatic rings, conjugated alkenes and 
an aliphatic portion. It seems that only one methyl group is present in CAP-1. 
 
30.2.2 Interpretation of 
13
C NMR spectra 
 
Two 
13
C NMR spectra from CAP-1 are placed between the final pages of this Master’s thesis 
(Supplementary material 1.3 and Supplementary material 1.4). One spectrum displays the peaks 
yielded by all the carbons in CAP-1, while the other spectrum is a close-up of the carbons further 
downfield (to the left). The former spectrum ranges from 185-10 ppm, while the latter ranges from 
170-113 ppm. These NMR spectra were interpreted prior to comparison of chemical shifts with 
published chemical shifts from a previously isolated organic compound (Table 30.2). 
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Table 30.2 Interpretation of 
13
C NMR spectra from CAP-1 
 
ppm Assignment 
179.1 Carbonyl 
168.5 Carbonyl or alkene (conjugated or 
bound to a polar substituent) 
168.2 Carbonyl or alkene (conjugated or 
bound to a polar substituent) 
165.9 Carbonyl or alkene (conjugated or 
bound to a polar substituent) 
161.7 Carbonyl or alkene (conjugated or 
bound to a polar substituent) 
161.3 Carbonyl or alkene (conjugated or 
bound to a polar substituent) 
159.3 Carbonyl or alkene (conjugated or 
bound to a polar substituent) 
158.5 Carbonyl or alkene (conjugated or 
bound to a polar substituent) 
147.4 Aromatic or alkene (both 
conjugated and unconjugated) 
147.0 Aromatic or alkene (both 
conjugated and unconjugated) 
134.7 Aromatic or alkene (both 
conjugated and unconjugated) 
133.9 Aromatic or alkene (both 
conjugated and unconjugated) 
132.0 Aromatic or alkene (both 
conjugated and unconjugated) 
131.3 Aromatic or alkene (both 
conjugated and unconjugated) 
127.1 Aromatic or alkene (both 
conjugated and unconjugated) 
122.5 Aromatic or alkene (both 
conjugated and unconjugated) 
116.8 Aromatic or alkene (both 
conjugated and unconjugated) 
116.6 Aromatic or alkene (both 
conjugated and unconjugated) 
114.9 Aromatic or alkene (both 
conjugated and unconjugated) 
114.6 Aromatic or alkene (both 
conjugated and unconjugated) 
105.9 Alkene or aromatic 
100.0 Alkene or aromatic 
99.2 Alkene or aromatic 
94.9 Alkene or aromatic 
74.6 C-O-C or CH-OH 
73.1 C-O-C or CH-OH 
69.7 C-O-C or CH-OH 
68.5 C-O-C or CH-OH 
17.7 Methyl 
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Twenty-nine chemically different carbons are present in CAP-1. Table 30.2 strongly suggests that 
there is at least one carbonyl group present in CAP-1, but there may be several as well. It appears that 
CAP-1 consists of aromatic rings, conjugated alkenes, ether groups and/or alcohol groups. This is 
consistent with interpretations from the 
1
H NMR spectra. Only one methyl groups is confirmed to be 
present in CAP-1.  
 
30.2.3 Interpretation of DEPT-135 spectrum  
 
A single DEPT-135 spectrum from CAP-1 can be found between the final pages of this Master’s thesis 
(Supplementary material 1.5). Only carbons with chemical shifts from 155-15 ppm were recorded. 
Interpretation of this DEPT-135 spectrum was done prior to comparison of chemical shifts with 
published chemical shifts of a previously isolated organic compound (Table 30.3). 
 
 
 
Table 30.3 Interpretation of DEPT-135 spectrum from CAP-1 
 
ppm Signal Assignment 
147.4 Positive CH (aromatic or alkene) 
147.0 Positive CH (aromatic or alkene) 
134.7 - Quaternary carbon 
133.9 Positive CH (aromatic or alkene) 
132.0 Positive CH (aromatic or alkene) 
131.3 Positive CH (aromatic or alkene) 
127.1 - Quaternary carbon 
122.5 - Quaternary carbon 
116.8 Positive CH (aromatic or alkene) 
116.6 Positive  CH (aromatic or alkene) 
114.9 Positive CH (aromatic or alkene) 
114.6 Positive CH (aromatic or alkene) 
105.9 - Quaternary carbon 
100.0 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
99.2 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
94.9 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent)  
74.6 Positive CH (CH-O-C or CH-OH)  
73.1 Positive CH (CH-O-C or CH-OH) 
69.7 Positive CH (CH-O-C or CH-OH) 
68.5 Positive CH (CH-O-C or CH-OH) 
17.7 Positive CH3 
 
 
 
It is obvious from Table 30.3 that there are no methylene groups in CAP-1, even though the carbons 
furthest downfield were not recorded on the DEPT-135 spectrum. This is true because carbons that are 
furthest downfield are either carbonyls or conjugated alkenes as discovered in the interpretation of the 
13
C NMR spectra. A total of four quaternary carbons are present in CAP-1. Majority of carbons are 
either aromatics or alkenes. Only a small portion of carbons are aliphatics.  
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30.2.4 Comparison of CAP-1 with a published compound 
 
Due to the many possibilities of structures that can be proposed from the interpretations of the 
1
H 
NMR spectra, the 
13
C NMR spectra and the DEPT-135 spectrum, chemical shifts from CAP-1 have 
been compared to published chemical shifts from a previously isolated organic compound (Table 30.4 
and Table 30.5). 
 
 
 
Table 30.4 
1
H NMR chemical shifts from CAP-1 compared with published 
chemical shifts from kaempferol-3-O-(2ʹʹ, 4ʹʹ-di-E-p-coumaroyl)-
-L-rhamnopyranoside 
 
Proton CAP-1 (δ), multiplicity 
and coupling constant (Hz) 
Published (δ), multiplicity 
and coupling constant (Hz) 
H-6 6.18 (s) 6.23 (s) 
H-8 6.34 (s) 6.40 (s) 
H-2ʹ 7.79 (d, 9) 7.82 (d, 8.5) 
H-3ʹ 7.04 (d, 9) 7.05 (d, 8.5) 
H-5ʹ 7.01 (d, 9) 7.05 (d, 8.5) 
H-6ʹ 7.76 (d, 9) 7.82 (d, 8.5) 
H-1ʹʹ 5.76 (s) 5.78 (s) 
H-2ʹʹ 5.58 (s) 5.56 (s) 
H-3ʹʹ 4.17 (dd, 3, 9) 4.18 (dd, 2.5, 10.0) 
H-4ʹʹ Approx. 5.00 (br s) 4.99 (t, 10.0) 
H-5ʹʹ Approx. 3.30 (N/A) 3.30 (N/A) 
H-6ʹʹ 0.87 (d, 6) 0.87 (d, 6.0) 
H-2ʹʹʹ 7.47 (d, 9) 7.51 (d, 8.5) 
H-3ʹʹʹ 6.80 (d, 9) 6.82 (d, 8.5) 
H-5ʹʹʹ 6.77 (d, 9) 6.82 (d, 8.5) 
H-6ʹʹʹ 7.44 (d, 9) 7.51 (d, 8.5) 
H-7ʹʹʹ 7.65 (d, 15) 7.70 (d, 16.0) 
H-8ʹʹʹ 6.43 (d, 15) 6.44 (d, 16.0) 
H-2ʹʹʹʹ 7.54 (d, 6) 7.55 (d, 8.5) 
H-3ʹʹʹʹ 6.83 (d, 9) 6.85 (d, 8.5) 
H-5ʹʹʹʹ 6.80 (d, 9) 6.85 (d, 8.5) 
H-6ʹʹʹʹ 7.52 (d, 6) 7.55 (d, 8.5) 
H-7ʹʹʹʹ 7.60 (d, 15) 7.59 (d, 16.0) 
H-8ʹʹʹʹ 6.32 (d, 15) 6.32 (d, 16.0) 
 Source: Wang, G. J., et al [33] 
  
s = singlet, d = doublet, dd = double doublet, t = triplet, N/A = not applicable 
 
 
 
As can be seen from Table 30.4, chemical shifts from protons in CAP-1 are fairly similar to chemical 
shifts from protons in the published compound. Multiplicities and coupling constants are practically 
the same. H-2ʹʹʹʹ and H-6ʹʹʹʹ display the largest differences in coupling constants (6 Hz in CAP-1 and 
8.5 Hz in the published compound). Not only are the chemical shifts similar, but also the number of 
protons are the same. To further prove their similarity, chemical shifts from carbons were compared as 
well (Table 30.5). 
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Table 30.5 
13
C NMR chemical shifts from CAP-1 compared with published 
chemical shifts from kaempferol-3-O-(2ʹʹ, 4ʹʹ-di-E-p-coumaroyl)--L-
rhamnopyranoside 
 
Carbon no. CAP-1 (δ) Published (δ) 
2 159.3 259.4 
3 134.7 134.7 
4 179.1 179.2 
5 161.7 163.3 
6 100.0 100.0 
7 165.9 166.0 
8 94.9 94.8 
9 158.5 158.6 
10 105.9 105.9 
1' 122.5 122.5 
2' 133.9 132.0 
3' 116.6 116.7 
4' 161.7 161.8 
5' 116.6 116.7 
6' 132.0 132.0 
1" 99.2 99.2 
2" 73.1 73.1 
3" 68.5 68.5 
4" 74.6 74.6 
5" 69.7 69.8 
6" 17.7 17.7 
1'" 127.1 127.2 
2'" 131.3 131.4 
3'" 116.8 116.8 
4'" 161.3 161.4 
5'" 116.8 116.8 
6'" 131.3 131.4 
7'" 147.4 147.4 
8'" 114.6 114.7 
9'" 168.2 168.2 
1"" 127.1 127.2 
2"" 131.3 131.4 
3"" 116.8 116.8 
4"" 161.3 161.4 
5"" 116.8 116.8 
6"" 131.3 131.4 
7"" 147.0 146.9 
8"" 114.9 115.0 
9"" 168.5 168.5 
  Source: Wang, G.J., et al [33] 
 
  Results and discussion 
65 
 
2 
4 
1’’’ 1’’’’ 
7’’’ 
7’’’’ 
A total of thirty-nine carbons are present in the published compound, but only twenty-nine of them are 
chemically different, which is in agreement with the interpretation of the 
13
C NMR spectra. Chemical 
shifts are so alike that they are practically the same. C-5 and C-2ʹ display the biggest differences in 
chemical shifts (δ 161.7 and δ 133.9 in CAP-1 and δ 163.3 and δ 132.0 in the published compound, 
respectively).  
 
The molecular formula of the published compound is C39H32O14, thus , the index of hydrogen 
deficiency is twenty-four. It consists of four aromatic rings, three conjugated alkenes, one sugar 
moiety, three carbonyl groups, four quaternary carbons and one methyl group. In addition, no 
methylene groups are present and its molecular weight is 724 Da. All of this is consistent with the 
interpretations of the MS spectra, the 
1
H NMR spectra, the 
13
C NMR spectra and the DEPT-135 
spectrum. Thus, CAP-1 was characterized as kaempferol-3-O-(2ʹʹ, 4ʹʹ-di-E-p-coumaroyl)--L-
rhamnopyranoside (Figure 30.2). 
 
 
 
Figure 30.2 Molecular structure of kaempferol-3-O-(2ʹʹ, 4ʹʹ-di-E-p-
coumaroyl)--L-rhamnopyranoside 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30.3 Structure elucidation of CAP-2 
 
Results from NMR and MS analysis of CAP-2 were inconclusive due to impurities in the sample. 
Further purification by a simple chromatographic technique would also be difficult to perform due to 
the small weight of the compound (11.7 mg). Thus, CAP-2 was not characterized. 
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30.4 Structure elucidation of CAP-3  
 
MS analysis of CAP-3 yielded quasi-molecular ions at m/z: 601 [M+Na]
+
 and 577 [M-H]
-
 in the 
positive ion mode and negative ion mode, respectively (Figure 30.3). Thus, the molecular weight of 
CAP-3 was calculated to be 578 Da. 
 
 
 
Figure 30.3 MS spectra from CAP-3 
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30.4.1 Comparison of CAP-3 with a published compound 
 
Due to the similarity between 
1
H NMR spectra, 
13
C NMR spectra and DEPT-235 spectra of CAP-1 
and CAP-3, chemical shifts from CAP-3 were compared with published chemical shifts from a 
previously isolated organic compound (Table 30.6 and Table 30.7). 
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Table 30.6 
1
H NMR chemical shifts from CAP-3 compared with published 
chemical shifts from kaempferol-3-O--L-(4ʹʹ-E-p-coumaroyl)-
rhamnoside 
 
Proton CAP-3 (δ), multiplicity 
and coupling constant (Hz) 
Published (δ), multiplicity 
and coupling constant (Hz) 
H-6 6.17 (s) 6.18 (d, 1.9) 
H-8 6.33-6.31 (d, 6) 6.34 (d, 1.9) 
H-2ʹ 7.74-7.71 (d, 9) 7.77 (d, 8.8) 
H-3ʹ Approx. 7.00 (m) 6.95 (d, 8.8) 
H-5ʹ Approx. 7.00 (m) 6.95 (d, 8.8) 
H-6ʹ 7.74-7.71 (d, 9) 7.77 (d, 8.8) 
H-1ʹʹ 5.62 (s) 5.49 (br s) 
H-2ʹʹ 4.25 (s) 4.23 (br s) 
H-3ʹʹ Approx. 3.90 (dd, N/A) 3.94 (dd, 3.4, 9.4) 
H-4ʹʹ Approx. 5.00 (br s) 4.95 (t, 9.4) 
H-5ʹʹ Approx. 3.30 (N/A) 3.30 (m) 
H-6ʹʹ 0.80-0.78 (d, 6) 0.80 (d, 6.0) 
H-2ʹʹʹ 6.33-6.31 (d, 6) 6.31 (d, 16.0) 
H-3ʹʹʹ 7.67 (m) 7.60 (d, 16.0) 
H-5ʹʹʹ 7.52-approx. 7.48 (d, 12) 7.53 (d, 8.6) 
H-6ʹʹʹ 6.82-6.79 (d, 9) 6.82 (d, 8.6) 
H-8ʹʹʹ 6.82-6.79 (d, 9) 6.82 (d, 8.6) 
H-9ʹʹʹ 7.52-approx. 7.48 (d,12) 7.53 (d, 8.6) 
 Source: Yang, N.Y., et al [34] 
 
 m = multiplet, br s = broad singlet 
 
 
 
Clearly, CAP-3 is not as pure as thought prior to MS and NMR analysis. This is evident by studying 
the many multiplets and unclear peaks displayed on the 
1
H NMR spectrum. Thus, many 
approximations had to be made when CAP-3 was compared to a published compound. However, only 
three peaks on the 
1
H NMR spectrum were not included in Table 30.6 (δ 7.50, δ 6.74 and δ 6.72), 
which gives a strong reason to believe that CAP-3 and the published compound are in fact the same 
compound. In spite of impurities, chemical shifts from CAP-3 and the published compound are very 
close to one another. Correct multiplicities and coupling constants are the most difficult to obtain from 
an impure 
1
H NMR spectrum. Majority of multiplicities are in agreement with the published 
compound, but majority of coupling constants are not. A total of fourteen chemically dissimilar 
protons are present both in the published compound and in CAP-3. Although the number of 
chemically dissimilar protons are the same, impurities can both display “false” peaks and hide “true” 
peaks on the spectrum. Thus, this number is rather uncertain. Chemical shifts from carbons in CAP-3 
were also compared to chemical shifts from carbons in the published compound (Table 30.7).   
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Table 30.7 
13
C NMR chemical shifts from CAP-3 compared with published 
chemical shifts from kaempferol-3-O--L-(4ʹʹ-E-p-coumaroyl)-
rhamnoside 
 
Carbon no. CAP-3 (δ) Published (δ) 
C-2 161.2 159.3 
C-3 133.9 135.5 
C-4 179.3 179.5 
C-5 163.1 163.3 
C-6 99.9 100.0 
C-7 165.7 166.4 
C-8 94.8 95.0 
C-9 158.4 158.7 
C-10 105.9 105.7 
C-1ʹ 122.6 122.0 
C-2ʹ 131.3 131.8 
C-3ʹ 116.8 116.8 
C-4ʹ 161.6 161.7 
C-5ʹ 116.5 116.8 
C-6ʹ 131.9 131.8 
C-1ʹʹ 102.1 102.1 
C-2ʹʹ 71.7 72.0 
C-3ʹʹ 70.1 70.3 
C-4ʹʹ 74.7 75.0 
C-5ʹʹ 69.6 70.1 
C-6ʹʹ 17.6 17.8 
C-1ʹʹʹ 168.7 168.8 
C-2ʹʹʹ 115.1 115.4 
C-3ʹʹʹ 146.7 146.8 
C-4ʹʹʹ 127.1 127.1 
C-5ʹʹʹ 131.9 132.1 
C-6ʹʹʹ 116.8 116.9 
C-7ʹʹʹ 161.5 161.0 
C-8ʹʹʹ 116.5 116.9 
C-9ʹʹʹ 132.0 132.1 
  Source: Yang, N.Y., et al [34] 
 
 
 
A total of twenty-six chemically dissimilar carbons are present in the published compound, while 
twenty-eight chemically dissimilar compounds are found in CAP-3. As explained earlier, this 
discrepancy might be due to impurities in the sample, but it might also be due to deviations in 
spectrometer measurements. Chemical shifts from the carbons in CAP-3 and chemical shifts from the 
carbons in the published compound are relatively similar. C-2 and C-3 display the largest differences 
in chemical shifts (δ 161.2 and δ 133.9 in CAP-3 and δ 159.3 and δ 135.5 in the published compound, 
respectively). Chemical shifts from the carbons in CAP-3 are far more similar to the published 
compound than the chemical shifts from the protons in CAP-3. This strengthens the suggestion that 
CAP-3 and the published compound are the same.  
 
 
 
  Results and discussion 
69 
 
30.4.2 Interpretation of DEPT-135 spectrum 
 
A single DEPT-135 spectrum from CAP-3 can be found among the final pages of this Master’s thesis 
(Supplementary material 1.8). The entire chemical shift range was recorded. Interpretation of this 
DEPT-135 spectrum from CAP-3 was used to confirm similarity (Table 30.8). 
 
 
 
Table 30.8 Interpretation of DEPT-135 spectrum from CAP-3 
 
ppm Signal Assignment 
179.3 - Quaternary carbon? 
168.7 - Quaternary carbon? 
165.7 - Quaternary carbon? 
163.1 - Quaternary carbon? 
161.6 - Quaternary carbon? 
161.5 - Quaternary carbon? 
161.2 - Quaternary carbon? 
158.4 - Quaternary carbon? 
146.7 Positive CH (aromatic or alkene) 
133.9 Positive CH (aromatic or alkene) 
132.0 Positive CH (aromatic or alkene) 
131.9 Positive CH (aromatic or alkene) 
131.3 Positive CH (aromatic or alkene) 
127.1 - Quaternary carbon? 
122.6 - Quaternary carbon? 
116.8 Positive CH (aromatic or alkene) 
116.5 Positive CH (aromatic or alkene) 
115.8 Positive CH (aromatic or alkene) 
115.1 Positive CH (aromatic or alkene) 
105.9 - Quaternary carbon? 
102.1 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
99.9 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
94.8 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
74.7 Positive CH (CH-O-C or CH-OH) 
71.7 Positive CH (CH-O-C or CH-OH) 
70.1 Positive CH (CH-O-C or CH-OH) 
69.6 Positive CH (CH-O-C or CH-OH) 
17.6 Positive CH3 
 
 
 
According to Table 30.8, as many as eleven quaternary carbons might be present in CAP-3. This is 
obviously incorrect due to the fact that carbons furthest downfield are carbonyls, aromatics or alkenes. 
Eleven quaternary carbons would require a substantial number of aromatic rings, cyclic aliphatics or 
alkynes. If eleven quaternary carbons were due to aromatics, a whole lot more peaks would be present 
on the 
13
C NMR spectrum; if eleven quaternary carbons were due to cyclic aliphatics, chemical shifts 
would concentrate upfield on the 
13
C NMR spectrum; if eleven quaternary carbons were due to 
alkynes, peaks would concentrate downfield on the 
13
C NMR spectrum; and if eleven quaternary 
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carbons were due to a combination of these structures, all the effects mentioned would appear on the 
13
C NMR spectrum. Thus, it unreasonable to believe that there are eleven quaternary carbons present 
in CAP-3. Since all of the NMR spectra from CAP-3 resemble the NMR spectra from CAP-1 to a 
great extent, it is more reasonable to assume that CAP-3 consists of only three quaternary carbons. 
Majority of carbons are therefore either aromatics or alkenes. Only a small portion of carbons are 
aliphatics. No methylene groups are present. 
 
The molecular formula of the published compound is C30H26O12, thus, the index of hydrogen 
deficiency is eighteen. It consists of three aromatic rings, two conjugated alkenes, one sugar moiety, 
two carbonyl groups, three quaternary carbons and one methyl group. In addition, no methylene 
groups are present and its molecular weight is 578 Da. Although impurities in CAP-3 impeded 
comparison of chemical shifts and interpretation of DEPT-235 spectrum, there exists strong proof that 
CAP-3 and the published compound are the same. Thus, CAP-3 was characterized as kaempferol-3-O-
-L-(4ʹʹ-E-p-coumaroyl)-rhamnoside (Figure 30.4). 
 
 
 
Figure 30.4 Molecular structure of kampferol-3-O--L-(4ʹʹ-E-p-coumaroyl)-
rhamnoside 
 
 
 
 
 
 
 
30.5 Structure elucidation of CAP-4   
 
Results from NMR and MS analysis of CAP-4 were inconclusive due to impurities in the sample. 
CAP-4 consisted of enough material for it to be further purified by a simple chromatographic 
technique (149.9 mg). Unfortunately, when the MS and NMR results came back, there was not enough 
time left to continue purification of CAP-4. Thus, CAP-4 was not characterized. 
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30.6 Structure elucidation of CAP-5 
 
MS analysis of CAP-5 yielded quasi-molecular ions at m/z: 471 [M+Na]
+
 and 919 [2M+Na]
+
 in the 
positive ion mode and quasi-molecular ions at m/z: 447 [M-H]
-
 and 895 [2M-H]
-
 in the negative ion 
mode (Figure 30.5). Thus, the molecular weight of CAP-5 was calculated to be 448 Da. 
 
 
 
Figure 30.5 MS spectra from CAP-5 
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30.6.1 Comparison of CAP-5 with a published compound 
 
1
H NMR spectra, 
13
C NMR spectra and DEPT-135 spectra from CAP-3 and CAP-5 are similar to one 
another, except for the fact that fewer protons and carbons are displayed on the 
1
H NMR spectrum and 
on the 
13
C NMR spectrum from CAP-5, respectively. This strongly suggests that CAP-5 is a smaller 
molecule than CAP-3, but that they share many similar structures. Chemical shifts from CAP-5 were 
compared to chemical shifts from a previously isolated organic compound (Table 30.9 and Table 
30.10). 
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Table 30.9 
1
H NMR chemical shifts from CAP-5 compared with published 
chemical shifts from quercitrin 
 
Proton CAP-5 (δ), multiplicity 
and coupling constant (Hz) 
Published (δ), multiplicity 
and coupling constant (Hz) 
H-6 6.12 (s) 6.15 (d, 1.6) 
H-8 6.28 (s) 6.32 (d, 2.0) 
H-2ʹ 7.30 (s) 7.29 (d, 2.1) 
H-5ʹ 6.89-6.86 (d, 9) 6.87 (d, 8.4) 
H-6ʹ 7.25-7.22 (d, 9) 7.26 (dd, 2.1, 8.0) 
H-1ʹʹ 5.31 (s) 5.31 (br s) 
H-2ʹʹ 4.22 (s) 3.96 (br s) 
H-3ʹʹ 3.78-3.75 (m) 3.33 (m) 
H-4ʹʹ Approx 3.30 (m) 3.09 (m) 
H-5ʹʹ Approx. 3.30 (m) 3.09 (m) 
H-6ʹʹ 0.91-0.89 (d, 6) 0.79 (d, 5.6) 
 Source: Yang, N.Y., et al [34] 
 
 
 
A total of ten chemically dissimilar protons are present in the published compound, which is exactly 
the same number of chemically dissimilar protons in CAP-5. Chemical shifts on both compounds are 
fairly similar. H-2ʹʹ, H-3ʹʹ, H-4ʹʹ and H-5ʹʹ display the least similar chemical shifts (δ 4.22, δ 3.78-3.75, 
δ 3.30 and δ 3.30 in CAP-5 and δ 3.96, δ 3.33, δ 3.09 and δ 3.09 in the published compound, 
respectively). Large differences in these chemical shifts might be due to deviations in spectrometer 
measurements and impurities in the sample. It is also worth mentioning that chemical shifts from H-
2ʹʹ, H-3ʹʹ, H-4ʹʹ and H-5ʹʹ in CAP-3 come much closer to CAP-5 than the published compound. This 
strengthens similarity between CAP-5 and quercitrin because CAP-3 has been identified to be an 
organic compound that is very similar to quercitrin. Majority of multiplicities are in accordance with 
the published compound. Coupling constants are very small in places where multiplicities are not in 
accordance, thus, split peaks might be left out from the full scale 
1
H NMR spectrum. Perhaps a close-
up would enable detection of splitting patterns with small coupling constants. Peaks with larger 
coupling constants are assigned both multiplicities and coupling constants that are in agreement with 
the published compound. To further prove their similarity, chemical shifts from carbons were also 
compared (Table 30.10). 
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Table 30.10 
13
C NMR chemical shifts from CAP-5 compared with published 
chemical shifts from quercitrin 
 
Carbon no. CAP-5 (δ) Published (δ) 
C-2 159.1 159.2 
C-3 136.1 136.1 
C-4 179.4 179.4 
C-5 162.9 162.9 
C-6 99.8 99.7 
C-7 165.8 165.7 
C-8 94.7 94.7 
C-9 158.3 158.4 
C-10 105.7 105.8 
C-1ʹ 122.9 122.9 
C-2ʹ 116.9 116.9 
C-3ʹ 146.1 146.3 
C-4ʹ 149.5 149.6 
C-5ʹ 116.3 116.3 
C-6ʹ 122.9 122.7 
C-1ʹʹ 103.3 103.4 
C-2ʹʹ 71.9 71.9 
C-3ʹʹ 71.9 72.0 
C-4ʹʹ 73.2 73.2 
C-5ʹʹ 71.8 71.8 
C-6ʹʹ 17.6 17.7 
  Source: Yang, N.Y., et al [34] 
 
 
 
A total of twenty-one chemically dissimilar carbons are present in the published compound, while 
nineteen chemically dissimilar carbons are present in CAP-5. This discrepancy might be due to similar 
chemical shifts between two pairs of carbons that make them appear on the same place on the 
13
C 
NMR spectrum. Thus, two chemically dissimilar carbons are left out. This explanation is confirmed by 
studying the DEPT-135 spectrum from CAP-5 which displays four peaks from δ 73.2-71.8, whereas 
the 
13
C NMR spectrum only displays three peaks in the same area. Chemical shifts from the carbons in 
CAP-5 and chemical shifts from the carbons in the published compound are so similar that they are 
practically equal. C-3ʹ and C-6ʹ display the largest differences in chemical shifts (δ 146.1 and δ 122.9 
in CAP-5 and δ 146.3 and δ 122.7 in quercitrin, respectively). However, differences in chemical shifts 
are so small that CAP-5 and quercitrin can be considered to be the same compound. 
 
30.6.2 Interpretation of DEPT-135 spectrum 
 
A single DEPT-135 spectrum from CAP-5 can be found between the final pages of this Master’s thesis 
(Supplementary material 1.11). Only carbons with chemical shifts from 137-15 ppm were recorded. 
Interpretation of this DEPT-135 spectrum from CAP-5 was used to confirm similarity (Table 30.11). 
 
 
 
 
 
 
 
  Results and discussion 
74 
 
2 
4 6 
8 
1’ 
1’’ 
Table 30.11 Interpretation of DEPT-135 spectrum from CAP-5 
 
ppm Signal Assignment 
136.1 - Quaternary carbon 
122.9 Positive CH (aromatic or alkene) 
116.9 Positive CH (aromatic or alkene) 
116.3 Positive CH (aromatic or alkene) 
105.7 - Quaternary carbon 
103.3 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
99.8 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
94.7 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
73.2 Positive CH (CH-O-C or CH-OH) 
71.9 Positive CH (CH-O-C or CH-OH) 
71.8 Positive CH (CH-O-C or CH-OH) 
17.6 Positive CH3 
 
 
 
It is clear from Table 30.11 that there are only two quaternary carbons present in CAP-5, although the 
carbons furthest downfield were not recorded. Reasons for this have previously been explained in the 
interpretation of DEPT-135 spectrum from CAP-3. CAP-5 consists mostly of aromatics and/or 
alkenes. Only a small portion of carbons are aliphatics, which most likely belong to a sugar moiety as 
in CAP-1 and CAP-3. Also there are no methylene groups present.  
 
The molecular formula of quercitrin is C21H20O11, thus, the index of hydrogen deficiency is twelve. It 
consists of two aromatic rings, one conjugated alkene, one sugar moiety, one carbonyl group, two 
quaternary carbons and one methyl group. In addition, no methylene groups are present and its 
molecular weight is 448 Da. All of this is consistent with comparison of NMR spectra and 
interpretation of the DEPT-135 spectrum. Thus, CAP-5 was characterized as quercitrin (Figure 30.6). 
 
 
 
Figure 30.6 Molecular structure of quercitrin 
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30.7 Structure elucidation of CAP-6  
 
CAP-6, as previously explained, was not sent to another laboratory at the Department of Natural 
Medicinal Chemistry for MS and NMR analysis because analytical TLC confirmed that CAP-6 and 
CAP-7 was the same compound. Thus, only one of them was analyzed. CAP-7 seemed purer and was 
therefore the obvious choice. 
 
 
30.8 Structure elucidation of CAP-7 
 
MS analysis of CAP-7 yielded quasi-molecular ions at m/z: 455 [M+Na]
+
 and 431 [M-H]
-
 in the 
positive ion mode and negative ion mode, respectively (Figure 30.7). Thus, the molecular weight of 
CAP-7 was calculated to be 432 Da. 
 
 
 
Figure 30.7 MS spectra from CAP-7 
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30.8.1 Comparison of CAP-7 with a published compound 
 
Resemblance with previously characterized compounds, strongly suggests that CAP-7 might be 
similar in structure as well. Due to difficulties in obtaining a single structure for CAP-7 by 
interpretation of NMR spectra alone, chemical shifts from CAP-7 were compared with chemical shifts 
from a previously isolated organic compound (Table 30.12). 
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Table 30.12 
1
H NMR chemical shifts from CAP-7 compared with published 
chemical shifts from afzelin 
 
Proton CAP-1 (δ), multiplicity 
and coupling constant (Hz) 
Published (δ), multiplicity 
and coupling constant (Hz) 
H-6 6.19-6.18 (d, 3.0) 6.15 (d, 2.0) 
H-8 6.37-6.36 (d, 3.0) 6.31 (d, 2.0) 
H-2ʹ 7.77-7.74 (d, 9.0) 7.73 (dd, 2.8, 8.8) 
H-3ʹ 6.94-6.92 (d, 6) 6.89 (dd, 2.8, 8.4) 
H-5ʹ 6.94-6.92 (d, 6) 6.89 (dd, 2.8, 8.4) 
H-6ʹ 7.77-7.74 (d, 9.0) 7.73 (dd, 2.8, 8.8) 
H-1ʹʹ 5.37 (s) 5.35 (s) 
H-2ʹʹ 4.23 (br s) 4.21 (br s) 
H-3ʹʹ 3.73 (m) 3.71 (m) 
H-4ʹʹ Approx. 3.30 (m) 3.33 (m) 
H-5ʹʹ Approx. 3.30 (m) 3.33 (m) 
H-6ʹʹ 0.93-0.91 (d, 6.0) 0.91 (d, 6.0) 
 Source: Yang, N.Y., et al [34] 
 
 
 
Chemical shifts from protons in CAP-7 are fairly similar to chemical shifts from protons in the 
published organic compound. H-8 displays the least similar chemical shift (δ 6.37-6.36 in CAP-7 and 
δ 6.31 in the published compound). Multiplicities and coupling constants are practically the same as 
well. Major differences between CAP-7 and the published compound are found in protons H-2ʹ, H-3ʹ, 
H-5ʹ and H-6ʹ. These protons should display double doublets, but they yield only doublets in the 1H 
NMR spectrum. Perhaps a close-up of the range 8.0-6.5 ppm would have made it possible to detect 
double doublets in the 
1
H NMR spectrum instead of only doublets. A total of nine chemically 
dissimilar protons are present both in CAP-7 and in the published compound. To further prove their 
similarity, chemical shifts from carbons were also compared (Table 30.13). 
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Table 30.13 
13
C NMR chemical shifts from CAP-7 compared with published 
chemical shifts from afzelin 
 
Carbon no. CAP-7 (δ) Published (δ) 
2 159.3 158.7 
3 136.2 133.9 
4 179.6 179.1 
5 163.1 162.2 
6 99.9 99.8 
7 165.8 165.3 
8 94.8 94.5 
9 158.5 158.3 
10 Approx. 105 104.2 
1ʹ 122.6 122.5 
2ʹ 131.9 132.2 
3ʹ 116.5 116.2 
4ʹ 161.6 159.4 
5ʹ 116.5 116.0 
6ʹ 131.9 132.2 
1ʹʹ 103.4 102.5 
2ʹʹ 72.0 71.6 
3ʹʹ 72.1 72.3 
4ʹʹ 73.2 73.2 
5ʹʹ 71.9 71.4 
6ʹʹ 17.6 17.8 
  Source: Bilia, A.R., et al [35] 
 
 
 
A total of nineteen chemically dissimilar carbons were found in CAP-7, while twenty dissimilar 
carbons are present in the published compound. A reason for this discrepancy might that the chemical 
shifts of two carbons are so close that they appear as one single peak. Perhaps a close-up of these 
carbons would display two peaks instead of only one. Chemical shifts between the two compounds are 
so similar that they are practically the same. C-3 and C-4ʹ display the most dissimilar chemical shifts 
(δ 136.2 and δ 161.6 in CAP-7 and δ 133.9 and δ 159.4 in the published compound, respectively). 
Both comparison of 
1
H NMR spectra and 
13
C NMR spectra strongly suggest that CAP-7 is in fact 
afzelin.  
 
30.8.2 Interpretation of DEPT-135 spectrum 
 
A single DEPT-135 spectrum from CAP-7 can be found between the final pages of this Master’s thesis 
(Supplementary material 1.14). The entire chemical shift range was recorded. Interpretation of this 
DEPT-135 spectrum from CAP-7 was used to confirm similarity (Table 30.14). 
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Table 30.14 Interpretation of DEPT-135 spectrum from CAP-7 
 
ppm Signal Assignment 
179.6 - Quaternary carbon? 
165.8 - Quaternary carbon? 
163.1 - Quaternary carbon? 
161.6 - Quaternary carbon? 
159.3 - Quaternary carbon? 
158.5 - Quaternary carbon? 
136.2 - Quaternary carbon? 
131.9 Positive CH (aromatic or alkene) 
122.6 - Quaternary carbon? 
116.5 Positive CH (aromatic or alkene) 
Approx. 105 - Quaternary carbon? 
103.4 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
99.9 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
94.8 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
73.2 Positive CH (CH-O-C or CH-OH) 
72.1 Positive CH (CH-O-C or CH-OH) 
72.0 Positive CH (CH-O-C or CH-OH) 
71.9 Positive CH ( CH-O-C or CH-OH) 
17.6 Positive CH3 
 
 
 
Table 30.14 suggests that there are as many as nine quaternary carbons present in CAP-7. This number 
is obviously too high to be correct, due to the fact that majority of carbons are further downfield, 
which indicates that they are carbonyls, alkenes or aromatics. The same reasons explained for CAP-3 
with regards to the number of quaternary carbons present also apply to CAP-7. Due to similarities with 
previously identified compounds and the number of chemically dissimilar carbons present in CAP-7, it 
is more likely that CAP-7 consists of only two quaternary carbons. Peaks furthest upfield in the 
DEPT-135 spectrum strongly suggests that there exists a similar sugar moiety in CAP-7 as those found 
in CAP-1, CAP-3 and CAP-5. No methylene groups are present. 
 
Afzelin has a molecular formula of C21H20O10, thus, the index of hydrogen deficiency is twelve. It 
consists of two aromatic rings, one conjugated alkene, one sugar moiety, one carbonyl group, two 
quaternary carbons and one methyl group. In addition, no methylene groups are present and its 
molecular weight is 432 Da. All of this is consistent with comparisons of chemical shifts from CAP-7 
with chemical shifts from afzelin and interpretation of the DEPT-135 spectrum. Thus, CAP-7 was 
characterized as afzelin (Figure 30.8). 
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Figure 30.8 Molecular structure of afzelin 
 
  
 
 
 
 
 
30.9 Structure elucidation of CAP-8 
 
Results from NMR and MS analysis of CAP-8 were inconclusive due to impurities in the sample. 
Further purification by a simple chromatographic technique would be difficult to perform due to the 
low weight of the compound (5.0 mg). Thus, CAP-8 was not characterized. 
 
 
30.10 Structure elucidation of CAP-9 
 
MS analysis of CAP-9 yielded quasi-molecular ions at m/z: 471 [M+Na]
+
 in the positive ion mode and 
quasi-molecular ions at m/z: 447 [M-H]
-
 and 895 [2M-H]
-
 in the negative ion mode (Figure 30.9). 
Thus, the molecular weight of CAP-9 was calculated to be 448 Da. This is the same molecular weight 
of CAP-5, which was identified as quercitrin. 
 
 
 
Figure 30.9 MS spectra from CAP-9 
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30.10.1 Comparison of CAP-9 with a published compound 
 
Since CAP-5 and CAP-9 yielded the same peaks on the MS spectra, it was natural to compare their 
NMR spectra as well. Not only were their MS spectra the same, but also their NMR spectra displayed 
a high degree of similarity. After such a comparison was made, the initial thought was that CAP-5 and 
CAP-9 was in fact the same compound. Thus, as for CAP-5, chemical shifts from CAP-9 were 
compared to chemical shifts from quercitrin (Table 30.15). 
 
 
 
Table 30.15 
1
H NMR chemical shifts from CAP-9 compared with published 
chemical shifts from quercitrin 
 
Proton CAP-9 (δ), multiplicity 
and coupling constant (Hz) 
Published (δ), multiplicity 
and coupling constant (Hz) 
H-6 6.20-6.19 (d, 3) 6.15 (d, 1.6) 
H-8 6.37 (d, N/A) 6.32 (d, 2.0) 
H-2ʹ 7.35-7.34 (d, 3) 7.29 (d, 2.1) 
H-5ʹ 6.93-6.90 (d, 9) 6.87 (d, 8.4) 
H-6ʹ 7.32-7.29 (d, 9) 7.26 (dd, 2.1, 8.0) 
H-1ʹʹ 5.35 (s) 5.31 (br s) 
H-2ʹʹ 4.22 (s) 3.96 (br s) 
H-3ʹʹ 3.78-3.74 (m) 3.33 (m) 
H-4ʹʹ 3.34 (m) 3.09 (m) 
H-5ʹʹ 3.34 (m) 3.09 (m) 
H-6ʹʹ 0.94-0.92 (d, 6) 0.79 (d, 5.6) 
 Source: Yang, N.Y., et al [34] 
 
 
 
A total of ten chemically dissimilar protons are present in the published compound, which is exactly 
the same number of chemically dissimilar protons in CAP-9. Chemical shifts on both compounds 
come somewhat close to one another. H-2ʹʹ, H-3ʹʹ, H-4ʹʹ and H-5ʹʹ display the least similar chemical 
shifts (δ 4.22, δ 3.78-3.74, δ 3.34 and δ 3.34 in CAP-9 and δ 3.96, δ 3.33, δ 3.09 and δ 3.09 in the 
published compound, respectively). These large differences in chemical shifts might be attributed to 
deviations in spectrometer measurements and impurities in the sample. It is also worth mentioning that 
chemical shifts from H-2ʹʹ, H-3ʹʹ, H-4ʹʹ and H-5ʹʹ in CAP-5 come much closer to CAP-9 than the 
published compound, which strengthens similarity between CAP-9 and quercitrin since CAP-5 has 
already been identified as quercitrin. Almost all multiplicities are in accordance with the published 
compound. Even small coupling constants are detected in the 
1
H NMR spectrum, many of which were 
not detected in the 
1
H NMR spectrum from CAP-5. Peaks with larger coupling constants are assigned 
both multiplicities and coupling constants that are in agreement with the published compound. To 
further prove similarity between CAP-9 and quercitrin, chemical shifts from carbons were also 
compared (Table 30.16). 
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Table 30.16 
13
C NMR chemical shifts from CAP-9 compared with published 
chemical shifts from quercitrin 
 
Carbon no. CAP-9 (δ) Published (δ) 
C-2 159.3 159.2 
C-3 136.2 136.1 
C-4 179.6 179.4 
C-5 163.1 162.9 
C-6 99.8 99.7 
C-7 165.8 165.7 
C-8 94.7 94.7 
C-9 158.5 158.4 
C-10 105.9 105.8 
C-1ʹ 123.0 122.9 
C-2ʹ 116.9 116.9 
C-3ʹ 146.3 146.3 
C-4ʹ 149.7 149.6 
C-5ʹ 116.4 116.3 
C-6ʹ 122.9 122.7 
C-1ʹʹ 103.5 103.4 
C-2ʹʹ 72.0 71.9 
C-3ʹʹ 72.1 72.0 
C-4ʹʹ 73.2 73.2 
C-5ʹʹ 71.9 71.8 
C-6ʹʹ 17.6 17.7 
  Source: Yang, N.Y., et al [34] 
 
 
 
A total of twenty-one chemically dissimilar carbons are present in the published compound, which is 
exactly the same number of chemically dissimilar carbons present in CAP-9. Chemical shifts from the 
carbons in CAP-9 and chemical shifts from the carbons in the published compound are so similar that 
they are practically the same. The largest difference in chemical shift between two similar carbons is δ 
0.2, which is regarded as a minuscule, insignificant difference. Thus, Table 30.16 strongly suggests 
that CAP-9 and CAP-5 is the same compound, meaning that they both can be identified as quercitrin. 
 
30.10.2 Interpretation of DEPT-135 spectrum 
 
A single DEPT-135 spectrum from CAP-9 can be found as the last page of this Master’s thesis 
(Supplementary material 1.17). Only carbons with chemical shifts from 140-15 ppm were recorded. 
Interpretation of this DEPT-135 spectrum from CAP-9 was used to confirm similarity (Table 30.17). 
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Table 30.17 Interpretation of DEPT-135 spectrum from CAP-9 
 
ppm Signal Assignment 
136.2 - Quaternary carbon 
123.0 - Quaternary carbon? 
122.9 Positive CH (aromatic or alkene) 
116.9 Positive CH (aromatic or alkene) 
116.4 Positive CH (aromatic or alkene) 
105.9 - Quaternary carbon 
103.5 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
99.8 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
94.7 Positive CH (aromatic or alkene, alkane 
only if bound to a polar substituent) 
73.2 Positive CH (CH-O-C or CH-OH) 
72.1 Positive CH (CH-O-C or CH-OH) 
72.0 Positive CH (CH-O-C or CH-OH) 
71.9 Positive CH (CH-O-C or CH-OH) 
17.6 Positive CH3 
 
 
 
There exists a possibility that CAP-9 consists of three quaternary carbons. However, there also exists a 
possibility that two carbons have come so close on the DEPT-135 spectrum that they have been 
detected as one single carbon. In addition, three quaternary carbons would require detection of more 
carbons on the 
13
C NMR spectrum. Thus, CAP-9 is more likely to consist of only two quaternary 
carbons. CAP-9 consists mostly of aromatics and/or alkenes. Only a small portion of carbons are 
aliphatics, strongly suggesting the presence of a sugar moiety. Also there are no methylene groups 
present.  
 
Quercitrin, as previously mentioned, consists of two aromatic rings, one conjugated alkene, one sugar 
moiety, one carbonyl group, two quaternary carbons and one methyl group. This is all consistent with 
comparison of NMR spectra and interpretation of the DEPT-135 spectrum. CAP-9 and quercitrin also 
share the same molecular weight. Thus, CAP-9 was also characterized as quercitrin (Figure 30.6). 
 
 
 
31. End results 
 
 
31.1 Summary of findings 
 
A total of nine compounds were isolated in the isolation process. Two of these were found to be the 
same compound on the basis of final TLC results, namely CAP-6 and CAP-7. Thus, only eight 
compounds were analyzed by MS and NMR. Comparison of MS and NMR spectra led to the 
discovery that CAP-5 and CAP-9 was the same compound as well. In addition, three out of the eight 
compounds sent for structure analysis were not pure enough to allow for structure characterization. As 
a result, out of the nine initially isolated and purified compounds, only four structurally dissimilar 
compounds were finally characterized (Table 31.1).   
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Table 31.1 Isolated and identified compounds 
 
Name Identified as Weight (mg) 
CAP-1 Kaempferol-3-O-(2ʹʹ, 4ʹʹ-di-E-p-coumaroyl)-
-L-rhamnopyranoside 
69.1 
CAP-2 N/A 11.7 
CAP-3 Kaempferol-3-O--L-(4ʹʹ-E-p-coumaroyl)-
rhamnoside 
75.7 
CAP-4 N/A 149.9 
CAP-5 Quercitrin 85.3 
CAP-6 Afzelin 65.6 
CAP-7 Afzelin 23.0 
CAP-8 N/A 5.0 
CAP-9 Quercitrin 15.6 
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Conclusion 
 
 
 
Compounds originating from Abies pindrow branches and leaves were isolated and characterized. 
Abies pindrow is utilized in Ayurveda for the treatment of fever, inflammatory diseases, bronchitis and 
other ailments. Studies of Abies pindrow extracts have in fact been shown to exert therapeutic activity 
in preclinical animal models. As a consequence; isolation, characterization, screening and preclinical 
testing of compounds from this plant species could potentially lead to the discovery of novel lead 
therapeutic compounds. [28]  
 
A series of extractions and an initial silica gel column chromatography was performed by Dr. Li 
Yong-Li prior to my involvement in the purification process (Figure 24.1). His work yielded three 
separate fractions, namely Fraction 1, Fraction 2 and Fraction 3. These fractions were purified in a 
sequential manner through the use of simple chromatographic techniques. A total of four compounds 
were isolated from Fraction 1 (Figure 25.1), one compound was isolated from Fraction 2 (Figure 
26.1) and four compounds were isolated from Fraction 3 (Figure 27.1). 
 
Interpretation of MS spectra and NMR spectra led to the discovery that two out of five samples that 
were pure enough for structure determination, namely CAP-5 and CAP-9, were the same compound. 
Thus, a final count of four structurally dissimilar compounds were isolated and identified in this 
Master’s thesis. More precisely: CAP-1 was identified as kaempferol-3-O-(2ʹʹ, 4ʹʹ-di-E-p-coumaroyl)-
-L-rhamnopyranoside (Figure 30.2); CAP-3 was identified as kaempferol-3-O--L-(4ʹʹ-E-p-
coumaroyl)-rhamnoside (Figure 30.4); CAP-5 and CAP-9 were identified as quercitrin (Figure 30.6); 
and CAP-7 was identified as afzelin (Figure 30.8). 
 
All identified compounds belong to a class of plant secondary metabolites called flavonoids. Humans 
are unable to synthesize flavonoids. Previous studies have shown that these compounds display 
antioxidant, anti-inflammatory and other cardiovascular protective properties in humans, even in small 
amounts. Thus, flavonoids are being extensively studied with regards to their potential therapeutic 
effects on human diseases, including cancer. The flavonoids isolated in this Master’s thesis are more 
specifically called flavonoid glycosides. [36, 37]  
 
Unfortunately, % yield of identified compounds in the branches and leaves of Abies pindrow is 
impossible to calculate due to the fact that no dry weight of material was provided. Only four 
structurally dissimilar compounds were identified although a total of nine compounds were initially 
isolated. All of the characterized compounds have previously been reported in the literature. The fact 
that three of the isolated compounds were not pure enough for structure elucidation could perhaps 
have been avoided by the use of more advanced chromatographic techniques such as HPLC, gas 
chromatography (GC) or counter current chromatography. Simple chromatographic techniques such as 
those described in this Master’s thesis are most commonly employed at the MRCTCM.  
 
Characterized compounds from this Master’s thesis will be incorporated to the Natural Products 
Library at the MRCTCM. The MRCTCM has developed an MDL database to provide a platform for 
professors, scientists and students to update and add new information about their compounds and to 
allow for easy access of all the research material performed at the MRCTCM. 
 
Larger amounts of compounds would be required to perform both in vitro screening and preclinical 
testing of the characterized compounds in this Master’s thesis. Thus, future work with these flavonoid 
glycosides depends on the isolation of larger quantities of material. If sufficient quantities are 
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obtained, future work could involve the study of these compounds on a molecular and on a cellular 
level. Hopefully, antitumor activity from initial screening tests would support further investigation in 
animal models.
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